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AMBER THOMPSON BRADLEY. E3 Ligase Identified by Differential Display 
(EDD) enhances cell survival and cisplatin resistance in epithelial ovarian cancer 
and oral squamous cell carcinoma. (Under the direction of Scott Eblen). 
 
 
EDD (E3-ubiquitin ligase identified by Differential Display) is an E3 ubiquitin 
ligase that is overexpressed in ovarian cancer, but is rare in benign and 
borderline tumors. EDD is also overexpressed in recurrent, platinum-resistant 
ovarian cancers and is associated with a two-fold increased risk of disease 
recurrence and death in ovarian cancer patients, suggesting a role in tumor 
survival and/or platinum resistance. EDD knockdown by siRNA induced 
apoptosis in A2780ip2, OVCAR5, and ES-2 ovarian cancer cells, correlating with 
a loss of the anti-apoptotic protein Mcl-1 through a GSK-3β-independent 
mechanism. Transient knockdown of EDD or Mcl-1 induced comparable levels of 
apoptosis in A2780ip2 and ES-2 cells. Stable overexpression of Mcl-1 protected 
cells from apoptosis following EDD knockdown, accompanied by a loss of 
endogenous, but not exogenous, Mcl-1 protein, indicating that EDD may regulate 
Mcl-1 synthesis. Indeed, EDD knockdown induced a 1.87-fold decrease in Mcl-1 
mRNA and EDD transfection enhanced murine Mcl-1 promoter driven luciferase 
expression five-fold. To separate EDD survival and potential cisplatin resistance 
functions, we generated EDD shRNA stable cell lines that could survive initial 
EDD knockdown and demonstrated that these cells were four- to 21-fold more 
xii 
 
sensitive to cisplatin. Moreover, transient EDD overexpression in COS-7 cells 
was sufficient to promote cisplatin resistance 2.4-fold, dependent upon its E3 
ligase activity. In vivo, mouse intraperitoneal ES-2 and A2780ip2 xenograft 
experiments showed that mice treated with EDD siRNA by nanoliposomal 
delivery (DOPC) along with cisplatin had significantly less tumor burden than 
those treated with control siRNA/DOPC alone (ES-2, 77.9% reduction, p=0.004; 
A2780ip2, 75.9% reduction, p=0.042) or control siRNA/DOPC with cisplatin in 
ES-2 (64.4% reduction, p=0.035), with a trend in A2780ip2 (60.3% reduction, 
p=0.168). These results identify EDD as a dual regulator of cell survival and 
cisplatin resistance and suggest EDD is a therapeutic target for ovarian cancer. 
Additionally, edd is overamplified in oral squamous cell carcinoma of the tongue. 
Preliminary results in this carcinoma indicate similar roles of EDD in regulating 
cellular survival and cisplatin resistance as demonstrated in ovarian cancer.
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Ovarian cancer is the leading gynecological cancer and the fifth leading 
cause of cancerous deaths of females in the United States. Approximately 
20,000 women each year are diagnosed with this cancer with about 14,000 
women dying each year from this disease (Siegel, Naishadham et al. 2013). Most 
women will die from recurrence after their tumors are drug resistant. The death 
rate is high in ovarian cancer patients because symptoms are overlooked or 
patients are not diagnosed until the disease has advanced. Common symptoms 
such as abdominal bloating and pain are not present until the tumors have 
metastasized throughout the peritoneal cavity. Current conventional treatments 
include surgical debulking of the tumor or removal of the reproductive organs, 
along with chemotherapy treatment such as paclitaxel, cisplatin, and/or 
carboplatin. 
 Etiology of Epithelial Ovarian Cancer  
Over 85% of ovarian tumors are epithelial carcinomas, which are thought 
to arise from the ovarian surface epithelium (mesothelium) (Auersperg, Wong et 
al. 2001). Tumors can also develop out of germ cells or stromal cells, which 
maintain the structural integrity of the ovaries and supply hormones. The origin of 
ovarian cancer has been highly debated over the past decade. Research in 
patients with familial ovarian cancer, arising as a result of mutations in BRCA1, 
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BRCA2, or p53, has indicated that these cancers may originate from the fallopian 
tubes (Selvaggi 2000, Powell, Kenley et al. 2005, Medeiros, Muto et al. 2006, 
Lee, Miron et al. 2007, Mehrad, Ning et al. 2010, Kurman and Shih Ie 2011). 
More recent research has also linked the fallopian tubes to the origin of ovarian 
cancer in non-hereditary cases (Lee, Miron et al. 2007, Mehrad, Ning et al. 2010, 
Kurman and Shih Ie 2011). Most epithelial ovarian tumor cells resemble cells 
from the fimbria, the distal part of the fallopian tube. It is difficult to determine the 
etiology of ovarian carcinoma because patients are not usually diagnosed until 
they exhibit advanced stages of the disease. This is a result of the dismissal of 
common symptoms of ovarian cancer such as abdominal pressure, bloating, 
pelvic pain, nausea, constipation, loss of appetite, and loss of energy. These 
symptoms are vague and often associated with more common issues such as 
digestive problems, leading to their dismissal as symptoms of ovarian cancer. 
Left untreated, ovarian cancer typically spreads locally to the opposite ovary, 
uterus, and the intraperitoneal cavity. While rare, metastasis to the liver, adrenal 
glands, spleen, and lungs may occur in the most aggressive forms of cancer. The 
most prevalent form of ovarian cancer is serous epithelial cancer (Seidman, 
Horkayne-Szakaly et al. 2004). It is commonly believed now that serous ovarian 
cancer originates from the fallopian tube. Other epithelial ovarian carcinomas can 
be classified as mucinous, endometrioid, clear cell, transitional cell (Brenner 





 Risk Factors 
The most common risk factors for ovarian cancer are heredity. Other risk 
factors include hormonal and environmental sources. The tumor protein 53 (p53) 
is commonly mutated in many types of cancers, including ovarian cancer. The 
tumor suppressor p53 activates DNA damage repair when damage is sensed, 
resulting in cell cycle arrest until the damage is repaired and apoptosis if the 
damage is irreparable. Alterations in p53 exist in 96% of high grade ovarian 
serous carcinomas, the most common subtype of ovarian cancer, but are rare in 
low grade serous carcinomas (Green, Berns et al. 2006). Human epidermal 
growth factor receptor 2 (HER2) is overexpressed in many types of cancers as 
well and is associated with a poor prognosis in these patients. HER2 is a 
receptor in the ErbB family of receptors and this protein regulates the signaling 
pathways linked to promoting cell proliferation and prevention of apoptosis. 
Overexpression of HER2 is estimated to be present in 10% of ovarian cancers 
(Verri, Guglielmini et al. 2005). Mutations in BRCA1 and BRCA2 in patients 
indicate a 30% to 70% chance of developing ovarian cancer by the age of 70 
(Antoniou, Pharoah et al. 2003, Chen and Parmigiani 2007). BRCA proteins are 
involved in mismatch repair mechanisms to repair DNA damage in the double 
helix such as during homologous recombination. Alterations in the cyclin kinase 
inhibitors p21 and p27, and the cell cycle protein cyclin E (Bali, O'Brien et al. 
2004, Schmider-Ross, Pirsig et al. 2006, Nakayama, Nakayama et al. 2010) are 
also present in ovarian tumors. Alterations in other signaling pathways can also 
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occur as a result of mutations in KRAS (Vereczkey, Serester et al. 2011) and PI3 
kinase (p110 subunit) (Levine, Bogomolniy et al. 2005).  
Other risk factors related to the development of ovarian cancer include 
environmental and hormonal factors. These risks are related to the commonly 
believed predisposition to ovarian cancer – ovulation (Fathalla 1971). It has been 
a long held belief that ovarian cancer arises as a result of the disruption and 
repair of the epithelial cells in the ovary due to ovulation and the oocyte leaving 
the ruptured follicle. Supporting this theory, pregnancy and the use of oral 
contraceptives to regulate the ovulation cycle are well known to reduce the risks 
of developing ovarian cancer. Ovarian cancer typically affects menopausal and 
post-menopausal women. Infertility has been shown to increase the risk of 
ovarian cancer, but it is unclear whether this is due to the lack of pregnancy or 
the use of fertility drugs which promotes this effect. Since hormones control the 
ovulation cycle, gonadotropins (Cramer and Welch 1983), which stimulate the 
ovarian epithelium, and estrogens and androgens, which promote reproductive 
capabilities, are known to promote carcinogenesis (Parazzini, La Vecchia et al. 
1994, Karlan, Jones et al. 1995, Rodriguez, Calle et al. 1995, Silva, Tornos et al. 
1997). In the 1960s, an association was found between the use of talcum powder 
and an increased risk of ovarian cancer, which suggests that toxins can enter the 
genital track and migrate upward to the reproductive organs (Henderson, 
Hamilton et al. 1979, Harlow, Cramer et al. 1992, Huncharek, Geschwind et al. 




 Treatment of Ovarian Cancer 
 Standard treatment of ovarian cancer is a combination of cytoreductive 
surgery and chemotherapies such as taxane (paclitaxel) and platinum (cisplatin 
or carboplatin) drugs. These treatments have been the standard of care for 
ovarian cancer patients for the last few decades, indicating a need for updated 
strategies. Surgical cytoreduction may include a total hysterectomy, bilateral 
salpingo-oophoectomy (removal of the ovaries and fallopian tubes), removal of 
pelvic or para-aortic lymph nodes, and/or omentectomy (removal of the 
abdominal lining) (Kim, Ueda et al. 2012). Clear cell carcinomas are notoriously 
resistant to paclitaxel and carboplatin, so these tumors are typically treated with 
irinotecan and cisplatin. Chemotherapies that are under investigation are PARP 
inhibitors and bevacizumab, an antibody directed against vascular endothelial 
growth factor (VEGF). PARP inhibitors show promising results in patients with 
BRCA mutations, since both PARP and BRCA are involved in DNA damage 
repair.  
 Following drug activation by aqueous hydrolysis, cisplatin and carboplatin 
exert their activity through interaction with DNA, RNA, and protein with a 
cytotoxic effect mediated through the formation of interstrand and intrastand 
crosslinks in DNA, creating DNA adducts. This elicits a DNA damage response in 
the cell, where nucleotide excision repair and mismatch repair are able to repair 
the damage. If the damage is not repaired, then the DNA damage signals for 
apoptosis to occur. Cisplatin (cis-diammine dichloroplatinum (II)) was first 
discovered in 1965 as an inhibitor of proliferation by Rosenberg and colleagues 
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when studying Escherichia coli exposed to a current delivered by platinum 
electrodes (Rosenberg, Vancamp et al. 1965). It was discovered that a platinum 
complex, specifically the cis isomer, inhibited binary fusion in the bacteria. 
Carboplatin (cis-diammine (1,1-cyclobutanedicarboxylate) platinum (II)) was 
created as an analog to cisplatin to reduce severe side effects, such as 
nephrotoxicity (kidney damage), neurotoxicity (nerve damage), and ototoxicity 
(hearing loss). In clinical trials, carboplatin has the same efficacy as cisplatin in 
ovarian cancer, although cisplatin is still more effective in other types of cancer, 
such as head and neck cancer. Paclitaxel was first discovered and isolated from 
the bark of the Pacific yew tree (Taxus brevifolia) in 1967 (Wani, Taylor et al. 
1971). Paclitaxel exerts its effect through the stabilization of microtubules to 
ultimately prevent breakdown of microtubules during mitosis. 
 Recurrent Ovarian Cancer  
 The five year survival rate of ovarian cancer patients is low (35%) after 
treatment with surgical debulking and chemotherapy treatment (paclitaxel, 
carboplatin, and/or cisplatin) (Green, Berns et al. 2006). Initial response rates to 
surgery and chemotherapy is 70%-80% in ovarian cancer patients (du Bois, Luck 
et al. 2003, Ozols, Bundy et al. 2003). However, most patients will eventually 
relapse with a poor prognosis and progression-free survival time of only 18 
months in those with advanced disease (McGuire, Hoskins et al. 1996, Rubin, 
Randall et al. 1999). There are a multitude of proposed mechanisms of 
resistance to both platinum drugs and paclitaxel. Many mechanisms overlap as 
major mechanisms of resistance to various chemotherapeutic drugs (Siddik 
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2003). Table 1.1 contains a list of identified mechanisms of resistance to the 
platinum drugs and paclitaxel, although this table provides a selective number of 
mechanisms and is not meant to be an exhaustive description of mechanisms of 
resistance to these chemotherapies. Most methods of resistance are relevant to 
the mechanism of action of each drug, as described above, or its presence in the 
cell. Obviously, it is extremely difficult to target the potential cellular methods of 
resistance to these drugs, indicating the need for better therapeutics and/or 
chemotherapeutic drug combinations in an effort to decrease multidrug 
resistance in tumors.  
Table 1.1  
General Mechanisms of Resistance to Platinum Chemotherapy or Paclitaxel  
 
Resistance Mechanisms to Platinum 
Drugs 
Resistance Mechanisms to Paclitaxel  
 
Increased Efflux Drug Transporters (ABC, MDR transporters) 
Decreased Uptake Drug Transporters 
Loss of p53 Function 
Downregulation of Pro-apoptotic proteins (Bax, Bad) 
Upregulation of Anti-apoptotic proteins (Bcl-2, Bcl-XL, Mcl-2) 
Increased Drug Inactivation 
(Glutathione and metallothioneins) 
 
Increased DNA damage repair Modifications of Tubulin 
Increased MAPK pathway Delay in mitotic entry 
Ras mutation or overexpression  
HER2 overexpression  
Increased PI3K/Akt pathway  
  
MAP Kinase Signaling in Ovarian Cancer 
 Activating mutations of BRAF and KRAS are prevalent in low grade and 
borderline ovarian tumors (approximately 60%), but is rarely observed in high 
grade serous ovarian carcinomas (Singer, Oldt et al. 2003). These mutations are 
mutually exclusive. This indicates that activation of signaling through RAF and 
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RAS are important in the development of ovarian tumors. Downstream of RAF 
and RAS, the activation of the MAP (mitogen-activated protein) kinase pathway 
has been detected in 80% of low grade ovarian tumors and 40% of high grade 
tumors (Hsu, Bristow et al. 2004). The MAPK pathway is critical for the 
transmission of extracellular signals, such as a response to the presence of 
growth factors, stress, and cytokines, to intracellular signaling pathways. 
Activation of the MAPK pathway leads to the activation of protein kinases, 
transcription factors, and other nuclear proteins which can lead to extensive 
proliferation and evasion of apoptosis, promoting tumor development. 
Constitutive activation of the MAPK pathway also leads to alterations in other 
pathways, such as the Akt pathway, which also participates in the development 
of tumors. 
 The MAPK pathway includes three major pathways which are differentially 
regulated by extracellular signals and thus lead to unique intracellular signaling 
processes. This is illustrated in Figure 1.1 which depicts an extremely simplified 
view of MAPK signaling pathways. There are many other upstream and 
downstream proteins involved in each signaling cascade as well as considerable 
























































Cytokine    







Oral Squamous Cell Carcinoma 
 
 Approximately 41,380 Americans each year are diagnosed with cancers of 
the oral cavity or pharynx, affecting more males (29,620) than females (11,760) 
(Siegel, Naishadham et al. 2013). Almost 20% of Americans that are diagnosed 
with carcinoma affecting these tissues will die from this disease each year. 
Worldwide, cancers of the oral cavity and pharynx affect 337,931 people each 
year, with a rate of mortality of approximately 54% (Parkin, Bray et al. 2005).  
The five year survival in the United States has increased to about 65% 
(increased from 53% in the 1970s) (Siegel, Naishadham et al. 2013). In contrast, 
the five year survival in developing countries for these patients is only about 31% 
(Parkin, Bray et al. 2005). Diagnosis typically occurs in patients 50 years old or 
older.     
 Etiology 
 Squamous cell carcinomas of the oral cavity can affect the tongue, base of 
the tongue, tonsils, nasopharynx, pharynx, and larynx (Saba, Goodman et al. 
2011). Each of these carcinomas is distinct. This type of carcinoma affects 
squamous cells, a type of epithelial cell. Molecular changes in these cells leading 
to carcinoma include gene amplification or overexpression of oncogenes such as 
erbB2, epidermal growth factor receptor (EGFR), myc, and cyclin D1or mutations 
in tumor suppressors such as p53 or p16 (Mehrotra and Yadav 2006).   
 Risk Factors 
 The high prevalence of oral cancer around the world, especially in 
developing countries, is due to increased use of tobacco (either chewing or 
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smoking) and alcohol use, the primary causes of oral cancer. Viral infection with 
Human papillomavirus (HPV), commonly HPV 16 or HPV 18,  also increases the 
risk of oral cancer while infection with Epstein-Barr virus has been linked to 
cancers of the nasopharynx (Parkin, Bray et al. 2005). Often HPV infection 
occurs as a result of oral-genital contact. Tumors linked to these viruses are 
often easier to treat allowing for increased survival in these patients (Ang, Harris 
et al. 2010). Typically, cancers of the tongue are not related to HPV infection, but 
rather to tobacco and alcohol use. Radiation exposure and immune deficiency 
have also been implicated in the development of these carcinomas.   
 Treatment of Oral Squamous Cell Carcinoma 
 Initially most oral carcinomas are asymptomatic often leading to a late 
diagnosis. Oral screenings from a dentist are critical to the diagnosis of this 
disease before progression and metastasis occurs. Treatments for oral 
squamous cell carcinomas of the various oral regions include surgical removal of 
the tumor(s), radiation, and chemotherapies such as cisplatin, paclitaxel, and 5-
fluorouracil. Surgery and radiation are first line treatments with chemotherapy 
being used as an adjuvant therapy in patients with metastasis.  Metastasis to the 
lymph nodes makes treatment much more difficult and decreases survival in 
these patients.   
 Mechanisms of Resistance 
 
 As with other cancers, resistance to chemotherapy treatment is a common 
problem in oral squamous cell carcinoma, exacerbated by the fact that 
chemotherapy is typically not used as an intervention until the disease has 
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progressed to the lymph nodes. Cancers affecting the oral cavity are unique in 
that the environment of the oral cavity has increased acidity. This increased 
acidity can affect the absorption of chemotherapeutic agents in these tumor cells 
(Griffiths 1991). This unique environment is thought to be maintained by vacuolar 
ATPases in these epithelial cells (Newell, Franchi et al. 1993, Yamagata, Hasuda 
et al. 1998). Other causes of drug resistance in these cells are common causes 
such as the overexpression of multi-drug resistance proteins to export drug out of 
the cell before allowing a cellular effect, as well as effects on the cell cycle, 
apoptosis, drug inactivation, and alterations in critical cellular pathways such as 
ERK, Akt, and p53. These common resistance mechanisms are described in 
more detail in the previous section on mechanisms of resistance in ovarian 









The Nobel Prize in chemistry was awarded to Avram Hershko, Aaron 
Ciechanover, and Irwin Rose in 2004 for their work in the late 1970s to early 
1980s discovering the degradation of proteins by ubiquitination. Hershko and 
colleges used fractionation of cellular components of reticulocytes to purify and 
identify proteins involved in ATP dependent protein degradation (Ciechanover, 
Heller et al. 1980, Hershko, Ciechanover et al. 1980, Hershko, Eytan et al. 1982, 
Hershko, Heller et al. 1983, Ciechanover, Hod et al. 2012).   
Ubiquitin 
The 76 amino acid polypeptide ubiquitin is expressed in all eukaryotes and 
is highly conserved. Ubiquitin is encoded by multiple genes, often as an 
oligomer, and processed to monomeric forms in order to be activated and 
covalently linked to proteins. The addition of ubiquitin to proteins is generally 
associated with protein degradation by the 26S proteasome (Hough, Pratt et al. 
1986); however, dependent on the type of ubiquitin attachment, this may not 
always be the case. When a protein is labeled with a multi-ubiquitin chain by 
isopeptide bonds on Lys 6 (Nishikawa, Ooka et al. 2004), Lys 11, Lys 27, Lys 29 
(Chastagner, Israel et al. 2006), Lys 33 (Al-Hakim, Zagorska et al. 2008), or Lys 
63 (Deng, Wang et al. 2000, Wang, Deng et al. 2001, Herman-Bachinsky, Ryoo 
et al. 2007) of ubiquitin, this can regulate cellular activities independent of protein 
degradation, but these ubiquitin modifications can also signal for proteolysis. The 
initial ubiquitin is added to either the ε-amino group of lysine or the amino 
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terminal residue in the targeted protein (Ciechanover and Ben-Saadon 2004). 
Addition of a multi-ubiquitin chain on Lys 48 on ubiquitin is the prototypical 
ubiquitin modification on a protein to designate its degradation by the 26S 
proteasome. Monoubiquitination of proteins can regulate cellular functions or 
localization of the ubiquitylated protein (Levkowitz, Waterman et al. 1999, 
Mukhopadhyay and Riezman 2007). Ubiquitin-mediated cellular activities, 
independent of the proteasome, include kinase activation, transcription factor 
activation, protein translocation, endocytosis, lysosomal targeting, and DNA 
damage repair.  
Ubiquitination 
Ubiquitin activating E1 enzymes begin the ubiquitination pathway by 
binding to both MgATP and ubiquitin in order to form an activated ubiquitin 
adenylate (Haas and Rose 1982, Hershko, Heller et al. 1983). Then E1 protein 
can form a thiol-ester bond between a critical cysteine amino acid in E1 and the 
carboxyl-terminal glycine amino acid of ubiquitin. E1 is able to carry two 
ubiquitins, an ubiquitin adenylate and an ubiquitin linked by a thiol-ester bond to 
E1. E1 transfers the ubiquitin to an ubiquitin conjugating E2 enzyme, mediated 
through a cysteine in the active site of an E2, through transesterification.  Then 
E2 either transfers the ubiquitin directly to the conserved, critical cysteine residue 
in the HECT domain of HECT family E3 ubiquitin ligases or forms an isopeptide 
bond between the glycine in ubiquitin and an internal lysine residue on the 
substrate protein or a growing ubiquitin chain on the substrate protein. This 
general process is illustrated in Figure 1.2. As E3 ubiquitin ligases provide 
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specificity in the ubiquitination process, more than 600 genes encode E3 ligases 
whereas about 40 genes are used to encode E2 enzymes (Deshaies and 
Joazeiro 2009). While there are some E3-E2 combinations that are restricted, 
most E3 ligases can interact with multiple E2 enzymes. Some combinations also 
include a multi-subunit complex of E3 ligases, such as the SCF (Skp, Cullin, F-
box containing complex) or APC (Anaphase Promoting Complex), each of which 
can include several individual ubiquitin ligases in a complex.   
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Figure 1.2. Ubiquitination  




















 E3 Ubiquitin Ligases 
E3 ubiquitin ligases complete the ubiquitination process by attaching 
either monomeric ubiquitin or a multi-ubiquitin chain to specific target proteins. 
There are several different domains of E3 ubiquitin ligases, which are unique to 
ubiquitin ligases of different families. These distinctive domains include HECT 
(Homologous to E6-AP Carboxyl Terminus), RING (Really Interesting New 
Gene), U-box, PHD (Plant Homeo-Domain), and LAP (Leukemia-Associated 
Protein) domains, which are all critical in mediating the transfer of ubiquitin to 
protein substrates. The different families of E3 ubiquitin ligases and their 
distinctive features are summarized in Figure 1.3. HECT domain-containing E3 
ubiquitin ligases include a critical cysteine amino acid about 35 amino acids from 
the carboxy-terminus in their HECT domain of about 350 amino acids, which 
allows for ubiquitin to be transferred directly onto the E3 ligase before 
ubiquitination of the substrate occurs (Huibregtse, Scheffner et al. 1995). This 
also permits HECT E3 ligases to ubiquitinate themselves. The RING finger 
domain is designated by the presence of eight conserved cysteine and histidine 
amino acids which utilize two zinc ions to transfer ubiquitin onto a substrate. This 
domain is defined as Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-
Cys-X2-Cys, in which X is defined as any amino acid (Borden and Freemont 
1996). The PHD finger is similar to the RING finger motif, but has a histidine in 
the fourth position rather than a cysteine (Capili, Schultz et al. 2001).      
E3 ubiquitin ligases are notoriously large proteins with multiple domains 
allowing for protein-protein interactions, which permit the interaction with 
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potential ubiquitination targets. Unlike kinases, which have a catalytic binding 
pocket that is critical for the binding of ATP, an active site in a binding pocket is 
not present in E3 ubiquitin ligases. This makes the discovery of E3 ubiquitin 
ligase small molecule inhibitors extremely difficult. While targeting the 
protein/protein and protein/ubiquitin interaction domains may seem relevant, the 
promiscuity of ubiquitin ligases to interact with multiple E2 enzymes and 
substrates makes this a difficult proposition. Nutlin-3, a cis-imidazoline analog, 
binds to the E3 ubiquitin ligase Mdm2 to prevent its interaction with the tumor 
suppressor p53. The inhibition of this interaction leads to the accumulation of p53 
to promote apoptosis (Vassilev, Vu et al. 2004). Clinical trials have not been 
completed on this inhibitor and the effects of this inhibitor on normal cells has yet 
to be determined (Secchiero, Bosco et al. 2011).   
E3 enzymes are the ultimate determining factor for substrate specificity in 
the ubiquitination process (Hershko, Heller et al. 1986). Specificity is also 
conferred by the type of the ubiquitin attachment, including which lysine in the 
protein is targeted for ubiquitination, the type of isopeptide linkage (such as Lys 
6, Lys 48, Lys 63, etc.), the addition of one ubiquitin protein, or the addition of a 




Figure 1.3.  E3 Ubiquitin Ligases  






The 26S proteasome consists of a 20S proteasome in its catalytic core 
and two 19S caps on either end of the catalytic core (Arrigo, Tanaka et al. 1988, 
Hoffman, Pratt et al. 1992). The 19S cap, also known as PA700, recognizes 
ubiquitinated proteins that have been targeted for degradation. Ubiquitin is 
removed and recycled before proteins enter the proteolytic core of proteasomes. 
The 20S proteasome utilizes ATP to degrade folded proteins, unfolded proteins, 
and peptides. In order to prevent random degradation of proteins in the cell, the 
catalytic core is insulated by the two 19S caps on either end of the channel 
formed by the proteasome core (Glickman, Rubin et al. 1998).  
The 19S caps are made up of several different subunits to provide the 
complex with a range of activities including deubiquitination, recognition of 
ubiquitin, ATPase, and reverse chaperone activity to allow target proteins to be 
unfolded and funneled into the proteasome pore.  The 19S cap is composed of 
nine subunits in its base complex and eight subunits in its lid complex (Fang and 
Weissman 2004). The 20S proteasome core is comprised of four stacked rings 
with seven subunits, each ring made of either α type or β subunits (αββα). The 
rings composed of β subunits are dependent on the formation of the α subunit 
ring first. The two inner-most rings are composed of β subunits, which possess 
catalytic activity. The β subunits have a critical threonine amino acid at the amino 
terminus of the protein, which is exposed after a pro-sequence is cleaved off the 
protein. The exposed threonine acts as a nucleophile to cleave peptides 
(Kisselev, Songyang et al. 2000). Different types of protease activity (trypsin-like, 
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chymotrypsin-like, and caspase-like) are dependent of different types of β 
subunits (Heinemeyer, Fischer et al. 1997, Jager, Groll et al. 1999). The 
proteasome will cleave proteins until the peptides that remain are small enough 
to diffuse out of the proteasome.  
Most protease inhibitors are peptides which mimic the transition state of a 
peptide undergoing proteolysis, but in this case the peptide is unable to be 
cleaved. These inhibitors can either reversibly or irreversibly inhibit the 
proteasome, dependent on a covalent bond forming between the peptide inhibitor 
and the proteasome. For example, MG132 is a reversible proteasome inhibitor 
with the peptide sequence Z-Leu-Leu-Leu-CHO, which is a peptide aldehyde. 
Most proteasome inhibitors form a hemiacetyl complex with the critical threonine 
of the β subunits (Rock, Gramm et al. 1994).  
 Deubiquitinating Enzymes 
 Deubiquitinating enzymes include ubiquitin carboxy-terminal hydrolases 
(UBHs) and ubiquitin-specific processing proteases (UBPs).  UBPs generally 
remove ubiquitin from proteins with a multi-ubiquitin chain. UBHs are generally 
associated with generating free monomeric ubiquitins, either from a multi-
ubiquitin chain on targeted proteins or from ubiquitin genes that are translated 
into a poly-ubiquitin chain (Kim, Park et al. 2003). There are approximately 79 
deubiquitinating enzymes, each with specificity (Nijman, Luna-Vargas et al. 






EDD was initially discovered in humans as a progestin-regulated HECT 
family E3 ubiquitin ligase that was identified by differential display in T47D breast 
cancer cells (Callaghan, Russell et al. 1998). Thus, EDD is an abbreviation for 
E3 ubiquitin ligase identified by Differential Display. Other names for EDD include 
hyd (hyperplastic discs gene) and ubr5 (ubiquitin protein ligase E3 component N-
recognin 5). The first ortholog of this gene was discovered in Drosophila 
melanogaster as the hyperplastic discs’ tumor suppressor gene (Mansfield, 
Hersperger et al. 1994). In Drosophila melanogaster, EDD crucially regulates 
proliferation and differentiation via the hedgehog and decapentaplegic signaling 
pathways. EDD has also been identified in rat testis during postnatal 
development and was characterized as Rat100 (Oughtred, Bedard et al. 2002). 
In rat testis, mutants of the edd gene cause defects in spermatogenesis. EDD is 
ubiquitously expressed in humans with the highest levels present in testis, brain, 
pituitary, and kidney. Significant levels of EDD expression were also detected in 
the uterus, placenta, stomach, and prostate (Callaghan, Russell et al. 1998).  
The edd gene is located on chromosome 8q22.3 (Callaghan, Russell et al. 
1998). The EDD protein is over 300 kDa in size and encodes several functional 
domains which are depicted in Figure 1.4. EDD contains two nuclear localization 
signals, a Poly A Binding Protein homology domain, two regions for protein-
protein interactions (UBA, UBR), several potential steroid receptor binding motifs 
(indicated by * in Figure 1.4), and a HECT domain with a conserved cysteine 
residue, which is critical for the transfer of ubiquitin onto EDD and subsequently 
24 
 
onto a target protein. The resolved structure of the HECT domain of EDD is 
depicted in Figure 1.5. The structure of the UBA domain of EDD is illustrated in 
Figure 1.6.  EDD interacts with importin α5 to transport EDD into the nucleus 
(Henderson, Russell et al. 2002). This interaction occurs at EDD’s nuclear 
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Figure 1.7. Phosphorylation sites of EDD
 
  
EDD has multiple functions in the cell, which can be dependent or 
independent on its ubiquitin ligase activity
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inhibitor of PABP activity. EDD targets Paip2 for degradation, which 
overall translation by increasing the activity of PABP
2006). Another interaction which permits EDD to affect translation is an 
interaction with α4 phosphoprotei
(mammalian target of rapamycin) pathway, promoting translational initiation 
(McDonald, Sangster et al. 2010
domain of EDD. The α4 phosphoprotein can also interact with PABP itself. 
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β-catenin is the first protein that has been shown to be ubiquitinated by 
EDD, but not degraded as a consequence. EDD ubiquitinates β-catenin to 
increase its stability with ubiquitin chains linked by lysine residues 29 and 11 
(Hay-Koren, Caspi et al. 2011). This allows for an increase in transcription of 
Wnt-regulated and β-catenin regulated genes. Many of these genes are linked 
with the progression of cancer and poor prognosis in cancer patients. However, 
EDD was identified as an interacting partner of adenomatous polyposis coli 
(APC), which allows for the stabilization of APC to enhance its protein expression 
(Ohshima, Ohta et al. 2007). This also promotes the inhibition of β-catenin, a 
downstream target of APC, which suggests that EDD may have a role as a tumor 
suppressor in colorectal cancer, where alterations in APC are prevalent.  
Another ubiquitination target of EDD is DNA Topoisomerase II-binding 
protein (TopBP1). In cells without DNA damage, EDD mediates the ubiquitination 
and subsequent degradation of TopBP1 (Honda, Tojo et al. 2002). In response to 
DNA damage, TopBP1 is protected from ubiquitination due to phosphorylation to 
promote its co-localization with γ-H2AX at sites of DNA damage. TopBP1 is then 
able to protect the ends of the damaged DNA and facilitate their repair. Thus, 
EDD manages TopBP1 protein levels to coordinate DNA damage response.  
EDD also interacts with several proteins to modulate their activity. 
Henderson et al. reported an interaction between EDD and CHK2, a DNA 
damage checkpoint kinase (Henderson, Munoz et al. 2006). This interaction is 
required for the phosphorylation of CHK2 on threonine 68 and the resulting 
activation of CHK2 as a result of DNA damage detection. The CHK2 kinase 
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phosphorylates proteins in cells with damaged DNA to promote mitotic arrest, 
DNA damage repair, and apoptosis if the damage is irreparable (Bartek, Falck et 
al. 2001, Falck, Mailand et al. 2001, Stevens, Smith et al. 2003). EDD is critical to 
this response. Knockdown of EDD in cells prevents DNA damage response and 
CHK2 activation. Similarly, the depletion of EDD in cells leads to defective DNA 
damage checkpoint activation resulting in mitotic catastrophe. Loss of EDD 
increased protein expression of E2F1 and Cdc25A/C, while decreasing 
expression of p27 and p21, with or without the presence of DNA damage 
(Munoz, Saunders et al. 2007). The disruption of these cell cycle checkpoints 
leads to premature mitosis in the presence of DNA damage, buildup of polyploid 
cells, and ensuing apoptosis. Other indications that EDD is involved in regulating 
DNA include its interaction with CIB1, a DNA-dependent kinase-interacting 
protein, and interaction with PMS1 and PMS2 during mismatch repair 
(Henderson, Russell et al. 2002, Cannavo, Gerrits et al. 2007). Furthermore, 
EDD ubiquitinates TopBP1 (topoisomerase IIβ-binding protein) as mentioned 
above.  
In addition to EDD’s role in the DNA damage pathway, EDD was recently 
shown to cooperate with TRIP12, another E3 ubiquitin ligase, to control 
accumulation of RNF168 (Gudjonsson, Altmeyer et al. 2012). RNF168 is a critical 
component of a complex to promote the ubiquitination of histones as a response 
mechanism to DNA damage. The presence of EDD and TRIP12 are crucial to 
maintain RNF168 levels to prevent extensive chromatin ubiquitination from 
spreading to undamaged chromosomes. Confirming the results of this study, 
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Okamoto et al. then demonstrated that inhibition of RNF168 by EDD is able to 
impede chromosome end-to-end fusions (Okamoto, Bartocci et al. 2013). This 
ultimately allows for a complex including TRF2 to protect chromosome ends. 
These studies confirm a role for EDD is maintaining chromosome integrity.  
EDD interacts with a dual specificity tyrosine phosphorylation regulated 
kinase, DYRK2. DYRK2 acts as a scaffold for EDD, VPRBP, and DDB1 proteins 
in an E3 ubiquitin ligase complex (Maddika and Chen 2009). The interaction of 
these proteins, facilitated by DYRK2, mediates the phosphorylation and 
degradation of katanin p60. EDD is the catalytic E3 ubiquitin ligase to regulate 
the ubiquitination of katanin p60. Katanin p60 is a microtubule-severing agent, 
which is critical during anaphase of mitosis to allow for segregation of 
chromatids. If ubiquitination of katanin p60 is prevented, cells become polyploid. 
Additionally, through interaction with DYRK2, EDD promotes the ubiquitination 
and degradation of TERT, a catalytic subunit of telomerase (Jung, Wang et al. 
2013). Phosphorylation of TERT by DYRK2 during the G2/M phase of the cell 
cycle prompts interaction and ubiquitination from EDD leading to TERT 
degradation. Since TERT is a subunit of telomerase, this causes inhibition of 
telomerase.  
There have been conflicting reports regarding an interaction between EDD 
and the tumor suppressor protein p53. Research by Ling and Lin suggests that 
EDD prevents ATM (ataxia telangiectasia mutated) mediated phosphorylation of 
p53 on serine 15 (Ling and Lin 2011). The phosphorylation of p53 on this residue 
by ATM is required for activation of p53 regulated genes in response to DNA 
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damage. EDD silencing prompts p53 phosphorylation to activate p53 target 
genes even in the absence of DNA damage. This results in a decrease in cells 
entering S-phase. Previously, Munoz et al. demonstrated opposite results in their 
research indicating that depletion of EDD leads to an increase in the percentage 
of cells entering S-phase as well as opposite effects on p21 expression levels 
(Munoz, Saunders et al. 2007). Also, Saunders et al. showed that the phenotype 
in an EDD knockout mouse is not dependent on p53 expression, as shown in a 
p53 null mouse (Saunders, Hird et al. 2004). It was proposed that the differing 
conclusions from the two labs mentioned above are dependent on the cell types 
used in the experiments (Watts and Saunders 2011). 
EDD interacts with Ago1, Ago2, GSPT1/2, ATXN2, and DDX6 proteins in 
the Argonaute-miRNA complex through its PABP-C domain (Su, Meng et al. 
2011). Su et al. demonstrated that EDD is required for miRNA mediated silencing 
of genes through this interaction in mouse embryonic stem cells. This interaction 
is independent of ubiquitin ligase activity. MicroRNAs bind to partially 
complementary mRNAs to promote mRNA degradation and prevention of 
translation in targeted mRNAs.  
Through mass spectroscopic analysis, EDD was identified as a part of the 
HPV-18 (human papillomavirus) E6/E6AP complex, which is responsible for 
ubiquitination of substrates to target them for degradation (Tomaic, Pim et al. 
2011). Loss of EDD in this complex stimulates the activity of the complex to 
increase proteolysis while higher EDD levels provide protection for the targeted 
substrates. Tomaić et al. proposed that the alternations in EDD levels may occur 
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due to progression through the viral life cycle to allow for degradation of assorted 
protein substrates. This indicates a role for EDD in HPV driven malignancies. 
Another study indicating a role for EDD in the regulation of the progression of 
cancer found that the edd gene was upregulated after a second exposure of 
ultraviolet radiation in human keratinocytes (Gupta, Chakrobarty et al. 2006). The 
edd gene was subsequently downregulated in colony forming cells which were 
exposed to ultraviolet radiation multiple times. The mechanism behind this 
phenomenon was not elucidated.  
As detailed above, EDD has many cellular functions dependent on protein 
interactions and ubiquitination of target proteins (Figure 1.8). On a physiological 
level, EDD is highly associated with vascularization and the function of the 
protein myocardin. Edd knockout mice embryos (embryonic day 8.5-10.5) 
demonstrated an inability to develop the yolk sac and allantoic vasculature 
(Saunders, Hird et al. 2004). The defective development of the extra-embryonic 
environment resulted in lack of proliferation and increased apoptosis. While the 
knockdown of edd results in embryonic lethality, heterozygous mice developed 
normally and were able to produce offspring. EDD was also identified as an 
interacting partner for the transcription factor myocardin (Hu, Wang et al. 2010). 
EDD cooperates with myocardin to promote its stabilization and to induce 
expression of genes to regulate the differentiation of smooth muscle cells. 
Recently, a chromatin binding profiling experiment identified that EDD regulates 
the expression of ACVRL1, a regulator of angiogenesis (Chen, Yang et al. 2013). 
ACVRL1 is a serine/threonine protein kinase that responds to the TGF-β ligand. 
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The transcriptional regulation at the ACVRL1 promoter by EDD is required for 
blood vessel development and motility of endothelial cells during angiogenesis.  
This regulation of transcription is independent of EDD’s ubiquitin ligase activity. 
Interaction with the progesterone receptor allows EDD to potentiate 
expression of progestin-induced genes (Henderson, Russell et al. 2002). EDD 
also serves as a coactivator for vitamin D receptor-mediated transcription. EDD’s 
ability to act as a transcriptional coactivator for specific hormone receptors is 
independent of its ubiquitin ligase function. Since EDD is a progestin-regulated 





Figure 1.8. Cellular Functions of EDD
Figure 1.9. Separate Roles of EDD 




– Dependent or Independent of Ubiquitin 






EDD in Cancer 
Truncation mutants of EDD are frequently found in gastric and colorectal 
cancers (Mori, Sato et al. 2002). The gene locus of edd is overamplified in 
several cancers including ovarian, breast, hepatocellular carcinoma, and 
metastatic melanoma (Fuja, Lin et al. 2004). Another study by Clancy et al. also 
demonstrated that EDD is overexpressed in ovarian and breast cancers (Clancy, 
Henderson et al. 2003). Clancy et al. analyzed several different cancers for allelic 
imbalance of EDD and found that 42% of all cancers in the study had either 
allelic gain or loss of the edd gene. While edd overexpression is rare in benign 
and borderline ovarian cancers, 47% of all types of this cancer overexpress edd, 
with 73% of serous ovarian cancers, the most prevalent form of ovarian cancer, 
overexpressing edd. This information is depicted in Figure 1.10. Edd is also 
overexpressed in oral squamous cell carcinoma (50%), hepatocellular carcinoma 
(46%), breast cancer (31%), and metastatic melanoma (18%). In ovarian cancer, 
EDD mRNA levels are often upregulated or downregulated as well, as 
demonstrated in Figure 1.11. Approximately 31% of 316 ovarian serous 
cystadenocarcinoma tumor samples have alterations at the level of mRNA 




Figure 1.10. Allelic Imbalance of EDD from (Clancy, Henderson et al. 2003) 
 
“Key: allelic imbalance, heterozygote, uninformative homozygote, gap 
denotes no data available” 
 
Figure 1.11. EDD levels are regulated at the mRNA level through upregulation or 
downregulation (Adapted from www.cbioportal.org/ Ovarian Serous 
Cystadenocarcinoma (TCGA, Nature) (2011)) 
 
 
 Similarly, a gene cluster on chromosome 8q22, containing edd and grhl2, 
was identified to suppress death receptor expression (Dompe, Rivers et al. 
2011). This research also revealed that EDD is overexpressed in several cancer 
cell lines that are resistant to apoptosis mediated by death-receptor activation. 
Specifically, EDD and GRHL2 reduced the expression of the death receptors Fas 
and DR5.  Induction of apoptosis by death receptors such as Fas receptor and 
TRAIL receptor are detailed in the “Apoptosis” section, which describes the 
mechanism of extrinsic apoptosis (vide infra). Silencing of EDD, leading to 
increased expression of Fas and DR5, was shown to sensitize cancer cell lines 





to ligand induced death receptor activation resulting in apoptosis. This research 
suggests that overexpression of EDD, and GRHL2, may offer tumors a 
mechanism to evade apoptosis.  
EDD is implicated in the activation of necroptosis, a programmed form of 
necrosis which is caspase-independent. In response to caspase inhibition, RIP1 
kinase and EDD were discovered to mediate JNK activation, resulting in the 
transcription of TNFα (Christofferson, Li et al. 2012). EDD interacts with RIP1 
and potentially stabilizes this kinase. Through EDD’s interaction with RIP1, JNK 
is activated through an unidentified mechanism, which promotes TNFα 
transcription. Transcription of TNFα is mediated most likely through the 
transcription factors AP-1 and SP1. EDD is required for the production of TNFα 
due to caspase inhibition, but EDD does not have a role in TNFα-mediated 
necroptosis. Regulation of TNFα may also have roles in apoptosis and 
inflammation, although this has not been addressed.  
 High expression of EDD in women with serous ovarian carcinoma, who 
showed an initial response to chemotherapy, is associated with a two-fold 
increased risk of recurrence and death (O'Brien, Davies et al. 2008). Even 
though protein expression of EDD did not correlate with cisplatin resistance, 
O’Brien et al. demonstrated in a cisplatin-resistant ovarian cancer cell line 
(A2780-cp70) in which siRNA-mediated knockdown of EDD increased sensitivity 
to cisplatin. High EDD expression in serous ovarian tumors reduced the median 
relapse time by 2.2 months in these patients (from 17.3 to 15.1 months in 
patients with low EDD tumor expression). The increased risk of relapse, 
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associated with high EDD expression, decreased median overall survival of 
these patients to 33.2 months as compared to 42.5 months for patients with low 
EDD expression (O'Brien, Davies et al. 2008). These results emphasize the 
significance of EDD in ovarian cancer as well as a potential role in mediating 






 Apoptosis is defined as a normal cellular process of programmed death. 
Characteristics of apoptosis include membrane blebbing, DNA fragmentation, 
condensation of the chromatin, and cellular shrinkage. Carl Vogt was the first to 
describe the principle of apoptosis in 1842, but apoptosis was not characterized 
until 1965 (Clarke and Clarke 2012). John Kerr, Alastair Currie, and Andrew 
Wyllie defined apoptosis using an electron microscope (Kerr, Wyllie et al. 1972). 
Within tissues, apoptotic cells divide themselves into smaller membrane bound 
bodies which undergo phagocytosis from neighboring cells or other phagocytic 
cells. This maintains tissue homeostasis. Apoptosis is a highly regulated process 
and is controlled by a genetically defined program. Research in Caenorhabditis 
elegans first identified the critical genes involved in mediating apoptosis (nuc 1, 
ced 3, ced 4, ced 9) (Horvitz 1999). These genes were later found to be 
homologous to the human anti-apoptotic and apoptotic proteins described later 
(vide infra).  
 The stimulus for apoptosis determines the genetic program that is 
activated in the cell to trigger apoptosis or, in some cases, overcome the cell’s 
ability to prevent apoptosis. Extrinsic apoptosis is typically triggered through 
ligand binding and stimulation of a death receptor. Examples include tumor 
necrosis factor, Fas ligand, and tumor necrosis factor related apoptosis inducing 
ligand (TRAIL). These receptors have a cytoplasmic domain with a death domain 
which is critical to transmit the death signal from external stimuli to intracellular 
signaling pathways. Upon ligand binding, the death domain of the receptor can 
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recruit and bind to an adaptor protein. The adaptor protein (such as Fas 
Associated Death Domain and TRAIL Associated Death Domain) associates with 
procaspase 8 to form a death-inducing signaling complex (DISC) (Ashkenazi and 
Dixit 1998). This results in caspase 8 cleavage and activation. Caspases have 
proteolytic activity and are crucial for the cleavage and activation of the caspase 
cascade to execute apoptosis. 
 Intrinsic apoptosis is stimulated by stress, DNA damage, or withdrawal of 
growth factors, cytokines, or hormones. This pathway converges on the 
mitochondria where apoptosis is induced once a mitochondrial permeability 
transition pore is opened to decrease the mitochondrial membrane potential and 
release factors into the cytosol. The opening of this pore is tightly controlled by a 
balance of anti-apoptotic and pro-apoptotic Bcl-2 family proteins localized at the 
mitochondrial membrane. Anti-apoptotic proteins include Bcl-2, Bcl-XL, Bcl-XS, 
and Mcl-1. Pro-apoptotic proteins include Bax, Bak, Bad, Bim, Bid, Puma, Noxa, 
and Bik. The anti-apoptotic proteins exert their effect by heterodimerizing with the 
pro-apoptotic proteins. If the pro-apoptotic proteins are allowed to oligimerize, the 
mitochondrial pore will be formed from this oligomer. Once the mitochondrial 
pore is opened, factors such as cytochrome c, Smac/DIABLO, and 
endonucleases are released. Cytochrome c interacts with Apaf-1 and 
procaspase 9 to form an apoptosome resulting in caspase 9 cleavage and 
activation (Hill, Adrain et al. 2004).   
 The extrinsic apoptotic pathway can also intersect with the intrinsic 
pathway through caspase 8 mediated cleavage of the pro-apoptotic protein Bid to 
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tBid to allow for the formation of the mitochondrial pore (Li, Zhu et al. 1998). In 
the end, both the extrinsic and intrinsic pathways both converge on an execution 
pathway mediated through caspase 3, caspase 6, and caspase 7. These 
caspases cleave cellular substrates to induce apoptosis such as PARP, 
cytokeratins, endonucleases, and cytoskeletal proteins. This results in 
accumulation of DNA damage due to PARP cleavage, membrane blebbing, and 
cell shrinking due to degradation of cytoskeletal proteins and cytokeratins. Also, 
endonucleases degrade the chromosomal DNA. Ultimately, all of the normal 
cellular processes fail and apoptotic cells neglect maintenance of the 
phospholipid bilayer. This allows for phosphatidylserine to be exposed on the 
surface of these cells and their cellular fragments to serve as a signal for 













EDD regulates survival and cisplatin resistance in ovarian cancer cells and 





This hypothesis will be tested through the following specific aims: 
  
B.3. Specific Aims  
1. Identify the importance of EDD in regulating sur vival in ovarian 
 cancer 
1a: Establish if EDD knockdown with siRNA induces apoptosis in   
  ovarian cancer cell lines  
1b. Examine the changes in apoptotic and anti-apoptotic proteins due  
   to EDD knockdown resulting in apoptosis 
1c. Validate the importance of specific proteins by knockdown and  
   overexpression to induce apoptosis in ovarian cancer cells 
1d. Determine the mechanism by which EDD regulates alterations in  
   specific apoptotic and/or anti-apoptotic proteins 
 
2. Determine if EDD regulates cisplatin sensitivity  in ovarian cancer 
2a: Determine if EDD knockdown with siRNA and shRNA promotes   
  cisplatin sensitivity 
2b: Determine if EDD overexpression is sufficient to promote cisplatin   
  resistance 
2c: Establish if EDD is a therapeutic target in epithelial ovarian cancer  
  through EDD knockdown experiments in vivo 
 
3. Characterize the role of EDD in the regulation o f cisplatin   
  resistance in oral squamous cell carcinoma 
     3a. Generate inducible shRNA EDD knockdown cell lines 
     3b. Determine if EDD stable knockdown sensitizes squamous cell  
  carcinoma cell lines to cisplatin treatment  
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*Note: This chapter contains a portion of the paper : 
Carcinogenesis. 2014 May 1; volume 35, number 5, pages 1100-1109. 
EDD enhances cell survival and cisplatin resistance  and is a therapeutic 
target for epithelial ovarian cancer. 
Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O 'Connor M, Blumer 
JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, L opez-Berestein G, Sood 










Initial therapy for ovarian cancer involves surgical debulking combined 
with chemotherapy, which consists of platinum and paclitaxel; however, 
resistance to chemotherapy often occurs in recurrent tumors. One indicator of 
poor prognosis in recurrent ovarian cancer is the E3 ubiquitin ligase EDD (E3 
ligase identified by differential display), a 300kDa nuclear phosphoprotein that we 
previously identified as a direct substrate of the MAP kinase extracellular signal-
regulated kinase 2 (Henderson, Russell et al. 2002, Eblen, Kumar et al. 2003, 
O'Brien, Davies et al. 2008, Bethard, Zheng et al. 2011). EDD helps regulate the 
DNA damage response, mediates Chk2 kinase activation, and has been 
implicated in the S phase and G2/M DNA damage checkpoints (Henderson, 
Russell et al. 2002, Henderson, Munoz et al. 2006, Munoz, Saunders et al. 2007, 
Gudjonsson, Altmeyer et al. 2012). EDD also acts as a transcriptional co-
activator for the progesterone and vitamin D receptors, dependent upon its 
middle domain and independent of its E3 ligase activity (Henderson, Russell et 
al. 2002). 
EDD protein is overexpressed or mutated in several solid tumors including 
ovarian, breast, hepatocellular, tongue, gastric, and melanoma (Mori, Sato et al. 
2002, Clancy, Henderson et al. 2003, Fuja, Lin et al. 2004). EDD protein levels 
are low in benign ovarian tissue and borderline tumors, but overexpression is 
observed in 47% of ovarian cancer tumors overall, 73% of serous ovarian 
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tumors, and was associated with a 2-fold increased risk of recurrence and death 
in patients who had a favorable response to initial chemotherapy (Clancy, 
Henderson et al. 2003, O'Brien, Davies et al. 2008). In these results, I 
demonstrate that EDD directly contributes to cellular survival through 
upregulation of the anti-apoptotic protein myeloid cell leukemia sequence 1 (Mcl-




Materials and Methods 
Cell lines and antibodies 
ES-2 and TOV21G cells were from Runzhao Li, OVCAR3 cells were from Kristen 
Atkins, A2780 cells were from Andrew Godwin, A2780ip2 cells were from 
Charles Landen, OVCAR5 cells were from Thomas Hamilton and IOSE cells 
were from Nelly Auersperg. COS-1, HeLa, and SKOV-3 cells were from 
American Type Culture Collection (ATCC, Manassas, VA). Mcl-1 stable cells 
were generated by transduction with pBabe or pBabe-Flag-Mcl-1 (Addgene) and 
puromycin-resistant clones (A2780ip2) or populations (ES-2) were selected. 
Antibodies [poly(ADP-ribose) polymerase (PARP), Bcl2 family proteins, actin] 
were from Cell Signaling (Danvers, MA) and the EDD (M19) antibody was from 
Santa Cruz Biotechnology (Santa Cruz, CA). Lipofectamine 2000 (Invitrogen) 
was used for transfections, according to the manufacturer’s protocol. 
siRNA transfection 
Cell lines were transfected with 45 nmol of control or EDD siRNA (Sigma–
Aldrich). siRNA1: SASI_Hs01_00175227 (5′CCAUUUACCCUGGCUAGUA); 
siRNA2: SASI_Hs02_00348492 (5′GCGACUCUCCAUGGUUUCU). Mcl-1 
siRNA: SASI_Hs01_00162656 (5′GUAAUAGAACUAUGACUGU). Bcl-xL siRNA: 
SASI_Hs01_00165963 (5′CUGAUUGGUGCAACCCUUA). Glycogen synthase 
kinase 3 beta (GSK-3β) siRNA1: SASI_ Hs01_00192106 (5′GGACUAUGU 
UCCGGAAACA) and GSK-3β siRNA2: SASI_Hs01_00192105 (5′CACUCAA 
GAACUGUCAAGU). Twenty nanomoles of Mcl-1, Bcl-xL and GSK-3β siRNA 




Floating and adherent cells were lysed with M2 lysis buffer containing 0.5% 
sodium dodecyl sulfate (Eblen, Catling et al. 2001). Typically, 65 µg of protein 
lysate was separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (7–12% gradient gel) and immunoblotted proteins were 
visualized using enhanced chemiluminescence (Pierce). GSK-3β inhibitors used 
were LiCl (20mM, Sigma–Aldrich), TDZD-8 (10 µM) and L803-mts (20 µM, EMD 
Chemicals, Gibbstown, NJ). Cycloheximide (Sigma–Aldrich) was used at 50 
µg/ml. For caspase inhibition, cells were co-treated with siRNA and either 25 µM 
pan caspase inhibitor Q-VD-OPH (R&D Systems, Minneapolis, MN) or the 
negative control Z-FA-FMK (BD Pharmingen, Franklin Lakes, NJ).  
Crystal violet staining 
Cells were fixed with 4% paraformaldehyde, stained with 0.05% crystal violet in 
2% ethanol for 15 min, washed five times with phosphate-buffered saline and 
dried. Stained cells were solubilized with 2% sodium dodecyl sulfate in 
phosphate-buffered saline and absorbance was measured at 550 nm.  
Quantitative real-time PCR 
RNA was extracted using the Qiagen (Valencia, CA) RNeasy Plus Mini Kit and 
cDNA was synthesized using the Bio-Rad (Hercules, CA) iScript™ Advanced 
cDNA Synthesis Kit for RT-qPCR. Bio-Rad’s SsoAdvanced™ SYBR® Green 
Supermix was used for quantitative real-time PCR on an Eppendorf (Hauppage, 
NY) Mastercycler Realplex 2. The average fold change of the test sample over 
control sample was determined for each experimental condition with 
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normalization to two housekeeping genes, actin and glyceraldehyde 3-phosphate 
dehydrogenase. The Mcl-1 primer was from Integrated DNA Technologies 
(Coralville, IA) (forward: 5′-AAAGAGGCTGGGATGGGTTT-3′, reverse: 5′-CAAAA 
GCAAGCAGCACATTC-3′). The actin primer used was from Real-Time Primers 
(forward: 5′-GGACTTCGAGCAAGAGATGG-3′, reverse: 5′-AGCACTGTGT 
TGGCGTACAG-3′) along with glyceraldehyde 3-phosphate dehydrogenase 
(forward: 5′-GAGTCAACGGATTTGGTCGT-3′, reverse: 5′-TTGATTTTGG 
AGGGATCTCG-3′).  
Flow cytometry 
Floating and adherent cells were fixed in ethanol and stained with propidium 
iodide (Molecular Probes, Eugene, OR). DNA content was determined by flow 
cytometry and sub-2n cells were counted as apoptotic. The Student’s t-test was 
performed on three independent experiments done in duplicate.  
Luciferase assays 
HeLa cells were transfected with 40 ng TK Renilla luciferase, 400ng of the firefly 
luciferase plasmids p(−2389/+10)mcl-luc, p(−1289/+10)mcl-luc, p(−567/+10)mcl-
luc, p(-70/+10)mcl-luc, or empty mcl-luc (Chao, Wang et al. 1998) and 2 µg of 
either wild-type or mutant Flag-EDD or empty vector. Luciferase assays were 
performed at 48hr using the Dual Luciferase Reporter Assay (Promega) on a 
Monolight 2010 Luminometer (Analytical Luminescence, Ann Arbor, MI). Firefly 
luciferase activity was normalized to Renilla luciferase. The results are a 
combination of four independent experiments done in triplicate. After averaging 
over experimental replicates, a two-sample t-test was conducted for each 
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luciferase plasmid testing the effect of EDD or EDD mutant versus vector. Cell 





EDD knockdown induces apoptosis in ovarian cancer c ells 
Immunoblotting lysates from ovarian cell lines showed high EDD 
expression in five of seven ovarian cancer cell lines compared with the 
preneoplastic IOSE398 cell line, with the highest expression in ES-2, OVCAR5 
and A2780 cells (Figure 2.1A). To determine the effect of EDD knockdown, we 
transfected A2780ip2 (Figure 2.2A), ES-2 (Figure 2.2B) and OVCAR5 (Figure 
2.2C) cells with control siRNA or one of two EDD siRNAs. EDD siRNAs knocked 
down EDD protein expression, with siRNA1 having the strongest effect. 
Interestingly, cells transfected with EDD siRNA showed a significant reduction in 
cell number in all three cell lines within 48hr, as measured by quantitation of 
crystal violet staining, with the exception of siRNA2 in ES-2 cells (Figure 2.2D). 
Loss of cell viability after EDD siRNA1 transfection increased from 24 to 72hr 
(Figure 2.2E). To determine whether EDD knockdown induced apoptosis, lysates 
from floating and adherent siRNA-transfected cells were immunoblotted for 
cleavage of PARP, a substrate of caspases and an indicator of apoptosis. 
Enhancement of cleaved PARP relative to total PARP (cleaved plus uncleaved) 
was observed in all three cell lines after EDD siRNA transfection (Figure 2.1B–
D), with siRNA1 having a greater effect, coinciding with greater EDD knockdown, 
especially in ES-2 cells. A2780ip2 cells showed enhanced apoptotic sensitivity to 
EDD knockdown at earlier time points (Figure 2.1B). In addition, propidium iodide 
staining followed by flow cytometry showed significant apoptosis, measured by 
<2n DNA content, after 48hr of EDD knockdown in A2780ip2 (control = 5.8%; 
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EDD = 44.6%), ES-2 (control = 5.8%; EDD = 42.6%) and OVCAR5 (control = 
5.9%; EDD = 22.6%) cells (Figure 2.1E). The induction of apoptosis showed a 
temporal increase in both A2780ip2 (Figure 2.1F) and ES-2 cells (Figure 2.1G). 
The relatively rapid induction of apoptosis suggested a short EDD half-life and 
strong requirement for cell survival. Cycloheximide experiments demonstrated 









Figure 2.1.  EDD is overexpressed in ovarian cancer cell lines and EDD 
knockdown induces apoptosis. (A) EDD expression was determined by 
immunoblotting lysates from ovarian cell lines. (B) A2780ip2, (C) OVCAR5 and 
(D) ES-2 cells were transfected with control siRNA or one of two siRNAs to EDD. 
After transfection for the indicated time, floating and adherent cells were 
harvested and cell lysates were immunoblotted for EDD expression and PARP. 
Uncleaved (Un) and cleaved (Clv) PARP are indicated with arrows. (E) Cells 
were transfected with control siRNA or EDD siRNA1 for 48hr and floating and 
adherent cells were stained with propidium iodide. Flow cytometry was used to 
determine the percentage of cells with sub-2n DNA content, an indicator of 
apoptosis. The results are from three independent experiments. (F) A2780ip2 
cells were transfected with control siRNA or EDD siRNA1 for 12 or 24hr and 
lysates from floating and adherent cells were immunoblotted for EDD expression 
and PARP cleavage. (G) ES-2 cells were transfected with control siRNA or EDD 
siRNA1 for 24 or 48hr and lysates from floating and adherent cells were 
immunoblotted for EDD expression and PARP cleavage. (H) A2780ip2 cells were 
treated with 50 µg/ml of cycloheximide for the indicated time. Cell lysates were 
immunoblotted for EDD and actin. The number under each lane indicates the 
relative intensity of the EDD band compared with actin, with the amount in time 









Figure 2.2.   EDD knockdown reduces cellular survival. (A) A2780ip2, (B) ES-2 
and (C) OVCAR5 cells were transfected with control or EDD siRNAs for 24hr and 
immunoblotted for EDD expression. (D) EDD knockdown reduces cell viability. 
Cells were transfected with control or EDD siRNA for 24hr, fixed, stained with 
crystal violet, and photographed at 10X magnification. The cells were solubilized 
and crystal violet absorbance measured. The number under each photograph 
corresponds to absorbance relative to control siRNA in that cell line and 
statistical significance from control transfected cells (p<0.05) is indicated with an 
asterisk (*). The results are from three independent experiments. (E) A2780ip2 
cells were transfected with control siRNA or EDD siRNA1 for 24, 48, or 72hr and 





EDD knockdown causes loss of Mcl-1 through a degrad ation- independent 
mechanism 
To identify a potential mechanism of apoptosis induction, we 
immunoblotted siRNA-transfected cell lysates with antibodies to Bcl2 family 
members, which have both prosurvival and proapoptotic functions (Burlacu 2003, 
Ola, Nawaz et al. 2011). EDD knockdown resulted in specific downregulation of 
the prosurvival protein Mcl-1 in all three cell lines, correlating with increased 
PARP cleavage (Figure 2.3A), and Mcl-1 loss was detected using either EDD 
siRNA1 or siRNA2 (Figure 2.4A). Pretreatment of the cells with the pan caspase 
inhibitor Q-VD inhibited PARP cleavage and the loss of the proapoptotic caspase 
3 substrate p53 upregulated modulator of apoptosis (Puma) upon EDD 
knockdown, but did not inhibit loss of Mcl-1, suggesting that Mcl-1 loss was not a 
consequence of caspase action or apoptosis induction (Figure 2.3B) (Hadji, 
Clybouw et al. 2010). To compare the requirements for EDD and Mcl-1 in cell 
survival, we transfected cells with siRNA against EDD, Mcl-1, the prosurvival 
protein Bcl-xL, or control siRNA. Apoptotic cells were identified by propidium 
iodide staining. EDD or Mcl-1 siRNA induced equal and significant induction of 
apoptosis in A2780ip2 (control = 7.6%; EDD siRNA1 = 42%; Mcl-1 = 41.4%; Bcl-
xL = 16.9%) and ES-2 cells (control = 4%; EDD siRNA1 = 25.8%; Mcl-1 = 22.6%; 
Bcl-xL = 6.1%), whereas Bcl-xL knockdown induced less apoptosis that was only 
significantly different from control in A2780ip2 cells and much less than that 
induced by EDD or Mcl-1 siRNA (Figure 2.3C and D). Immunoblotting 
demonstrated knockdown of the targeted proteins and levels of PARP cleavage 
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that corresponded to the relative level of apoptosis observed by propidium iodide 
staining (Figure 2.3E). These data show that these ovarian cancer cell lines have 
the same survival requirement for EDD and Mcl-1. 
To determine if EDD regulated survival by promoting Mcl-1 levels, we 
generated stable cell lines expressing either Flag-Mcl-1 or empty vector. Stable 
ES-2 populations (Figure 2.3F) and A2780ip2 clones with varying levels of Flag-
Mcl-1 (Figure 2.3G) were selected with puromycin. Flag-Mcl-1 migrated slower 
than endogenous Mcl-1 on sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis. Flag-Mcl-1 overexpression inhibited PARP cleavage upon EDD 
knockdown in both ES-2 (Figure 2.3H) and A2780ip2 (Figure 2.3I) stable lines 
compared with the vector control lines, with a dose-dependent effect of 
exogenous Mcl-1 expression on inhibition of PARP cleavage in the A2780ip2 
clones. Interestingly, EDD knockdown induced loss of endogenous Mcl-1, but not 
expression of the exogenous Flag-Mcl-1 expressed from a cytomegalovirus 
promoter. Collectively, these results show that Mcl-1 overexpression protects 
cells from apoptosis upon EDD knockdown. 
Mcl-1 protein stability is controlled in part through phosphorylation by 
GSK-3β, stimulating Mcl-1 ubiquitination by β-transducin repeat-containing 
protein, followed by proteosomal degradation (Ding, He et al. 2007). EDD binds 
to GSK-3β and stimulates its nuclear accumulation (Hay-Koren, Caspi et al. 
2011). To determine if EDD binding to GSK-3β ‘protects’ Mcl-1 from GSK-3β-
induced degradation, which would be lost upon EDD knockdown, we transfected 
parental A2780ip2 cells with EDD siRNA1 and treated the cells with the GSK-3β 
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inhibitors TZDZ, lithium chloride or L803-mts (Klein and Melton 1996, Phiel and 
Klein 2001, Martinez, Alonso et al. 2002, Kaidanovich-Beilin and Eldar-Finkelman 
2006, Rao, Hao et al. 2007). GSK-3β inhibitors did not inhibit Mcl-1 
downregulation or PARP cleavage upon EDD knockdown (Figure 2.4B). 
Furthermore, GSK-3β knockdown for 24hr prior to EDD knockdown with siRNA1 
did not prevent the loss of Mcl-1 protein or inhibit PARP cleavage (Figure 2.4C), 










Figure 2.3.  EDD downregulation decreases Mcl-1 protein levels, whereas Mcl-1 
overexpression inhibits apoptosis upon EDD knockdown. (A) Cells were either 
untreated (none) or transfected with control or EDD siRNA1 for 24hr. Lysates 
from floating and adherent cells were immunoblotted for EDD, PARP and Bcl2 
family members as indicated. (B) A2780ip2 and ES-2 cells were untreated (none) 
or transfected with control siRNA or EDD siRNA1 and simultaneously treated 
with either Q-VD-OPH pan caspase inhibitor (+) or the negative control Z-FA-
FMK (−). After 24hr, floating and adherent cells were collected, lysed, run on 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and immunoblotted 
for EDD, PARP, Mcl-1, Bcl-xL, p53 upregulated modulator of apoptosis, and 
actin. (C) A2780ip2 and (D) ES-2 cells were either untreated (none) or were 
transfected with the control siRNA, EDD siRNA1, or siRNA to Mcl-1 or Bcl-xL for 
24hr. Floating and adherent cells were fixed, stained with propidium iodide, and 
the percentage of sub-2n cells determined by flow cytometry. P values represent 
significance compared with the control siRNA-transfected cells. (E) Cells were 
transfected with siRNA as in (D) for 24hr. Lysates from floating and adherent 
cells were immunoblotted to confirm knockdown and to determine PARP 
cleavage. (F) Stable populations of ES-2 cells and (G) stable clones of A2780ip2 
cells expressing either pBabe vector (Vec) or pBabe-Flag-Mcl-1 (Mcl-1) were 
generated by retroviral transduction. Cell lysates were immunoblotted as 
indicated. Arrows indicate endogenous Mcl-1 and the slower-migrating Flag-Mcl-
1. (H) Stable ES-2 or (I) A2780ip2 cells were transfected with control or EDD 
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siRNA1 for 24hr and cell lysates immunoblotted as indicated. Arrows indicate 






Figure 2.4.  EDD regulates Mcl-1 levels through a GSK-3β-independent 
mechanism. (A) A2780ip2 cells were transfected with control siRNA, EDD 
siRNA1, or EDD siRNA2 and cell lysates were immunoblotted for EDD, PARP, 
and Mcl-1. (B) Cells were either untreated (None) or transfected with control 
(Con) or EDD siRNA1 (si1) and treated with DMSO or the GSK-3β inhibitors 
TDZD-8, LiCl, or L803-mts. Floating and adherent cells were harvested at 24hr 
and cell lysates immunoblotted as indicated. (C) A2780ip2 cells were either 
untreated (None) or transfected with either control siRNA (Con) or either of two 
GSK-3β siRNAs. After 24hr, the cells were transfected again with either control 
(Con) or EDD siRNA1. After an additional 24hr, cell lysates from both floating 





EDD enhances Mcl-1 expression at the messenger RNA level 
The above results suggest that EDD may regulate Mcl-1 synthesis, not its 
degradation. Indeed, quantitative real-time PCR analysis demonstrated that EDD 
knockdown inhibited Mcl-1 messenger RNA (mRNA) expression by 1.87-fold in 
both A2780ip2 and ES-2 cells at 12 and 24hr, respectively, compared with 
transfection with control siRNA, demonstrating that EDD downregulation inhibits 
Mcl-1 transcription (Figure 2.5A). 
EDD has been shown to act as a transcriptional co-activator for the 
progesterone and vitamin D receptors, independent of the C-terminal ubiquitin 
ligase domain (Henderson, Russell et al. 2002). Flag-EDD co-transfection in 
HeLa cells enhanced transcription from an Mcl-1 promoter-driven luciferase 
reporter p(−2389/+10)mcl-luc by 5-fold when normalized to cotransfected TK 
Renilla luciferase (Figure 2.5B) (Chao, Wang et al. 1998). Transfection of the 
ubiquitin ligase-deficient point mutant, Flag-EDD-C2768A, also induced 
luciferase expression 5-fold. Western blotting confirmed equal EDD expression 
(Figure 2.5C). Regulation of the Mcl-1 promoter likely occurs at the region 70 to 
203 nucleotides preceding the transcriptional start site (Figure 2.5D).These data 
suggest that EDD positively regulates Mcl-1 transcription, independent of its 












Figure 2.5. EDD regulates Mcl-1 levels through transcriptional regulation. (A) 
EDD knockdown inhibits Mcl-1 mRNA expression. ES-2 and A2780ip2 cells were 
transfected with EDD siRNA1 for 24 or 12hr, respectively, and RNA was 
harvested. Quantitative real-time PCR was performed using Mcl-1-specific 
primers. The y-axis represents the fold change in Mcl-1 mRNA in EDD siRNA1-
transfected cells compared with that in control siRNA-transfected cells. The 
results are a combination of three independent experiments. (B) EDD activates 
the Mcl-1 promoter. HeLa cells were transfected with p(−2389/+10)mcl-luc, an 
Mcl-1 promoter-driven firefly luciferase plasmid, TK Renilla luciferase, and either 
Flag-EDD, Flag-EDD-C2768A, or empty vector. Cells were harvested at 48hr and 
firefly luciferase activity was normalized to Renilla luciferase activity in each 
sample. P values indicate significance (P < 0.05) within a group between Flag-
EDD- and vector-transfected cells. These results are a combination of four 
independent experiments. (C) Western blot of Flag-EDD from (B). (D) As in (B), 
HeLa cells were transfected with p(−2389/+10)mcl-luc, p(−1289/+10)mcl-luc, 
p(−567/+10)mcl-luc, p(-70/+10)mcl-luc, or empty mcl-luc, with p(-2389/+10) being 
the longest Mcl-1 promoter in the luciferase assay. HeLa cells were also 
transfected with TK Renilla luciferase and Flag-EDD or empty vector. After 48hr, 
luciferase activity was assayed and normalized to Renilla luciferase activity. This 
experiment is a representative experiment out of three experiments. An “*” 





This study illustrates that EDD enhances cell survival through the 
prosurvival protein Mcl-1, an important mediator of survival in ovarian cancer 
cells (Shigemasa, Katoh et al. 2002, Simonin, Brotin et al. 2009, Brotin, Meryet-
Figuiere et al. 2010). EDD knockdown inhibited Mcl-1 mRNA and endogenous 
protein expression, whereas EDD overexpression increased Mcl-1 transcriptional 
expression in luciferase assays using the murine Mcl-1 promoter. Induction of the 
Mcl-1 promoter was independent of EDD’s ubiquitin ligase activity, as mutation of 
the critical cysteine residue in the E3 ligase domain still allowed for induction of 
the Mcl-1 promoter. This is in agreement with a previous study that showed that 
EDD acted as a transcriptional co-activator through the middle third of the 
protein, independent of the C-terminal ubiquitin ligase domain (Henderson, 
Russell et al. 2002).  
Several transcription factors have been demonstrated to regulate Mcl-1 
expression, some of which have links to EDD. Platelet-derived growth factor 
stimulation of prostate cancer cells enhances Mcl-1 expression via a β-catenin 
and hypoxia-inducible factor 1 alpha subunit-dependent pathway and EDD 
ubiquitinates β-catenin to promote its stabilization, nuclear localization and 
activity (Hay-Koren, Caspi et al. 2011, Iqbal, Zhang et al. 2012). E2F 
transcription factor 1 represses Mcl-1 expression and knockdown of EDD 
induces E2F transcription factor 1 protein levels in HeLa cells (Croxton, Ma et al. 
2002, Munoz, Saunders et al. 2007). Transcription factor software analysis 
(TFSEARCH) of the human Mcl-1 promoter (accession no. DQ088966) identified 
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potential binding sites for other transcription factors, including GATAs 1–3, heat 
shock factors 1 and 2, nuclear factor kappa B and activator protein 1. The 
progesterone receptor cooperates with GATA-2 in transcriptional activation in 
breast cancer cells, suggesting that EDD–progesterone receptor interactions 
may regulate Mcl-1 expression through a GATA-2-dependent pathway 
(Henderson, Russell et al. 2002, Magklara and Smith 2009). We have not ruled 
out translational control of Mcl-1 expression by EDD as an additional mechanism 
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Initial therapy for ovarian cancer involves surgical debulking combined 
with chemotherapy, which consists of platinum and paclitaxel; however, 
resistance to chemotherapy often occurs in recurrent tumors. Identifying 
mechanisms of acquired drug resistance is important to developing novel 
therapeutics. One indicator of poor prognosis in recurrent ovarian cancer is the 
E3 ubiquitin ligase EDD (E3 ligase identified by differential display) (Clancy, 
Henderson et al. 2003).  E3 ubiquitin ligases modify proteins through the addition 
of ubiquitin, most often resulting in protein degradation (Wolf and Hilt 2004, 
Rechsteiner and Hill 2005). EDD contains a C-terminal HECT (Homologous to 
the E6-AP Carboxyl Terminus) ubiquitin ligase domain and is the human 
homolog of the Drosophila tumor suppressor hyperplastic discs (hyd), which 
regulates imaginal disk formation (Callaghan, Russell et al. 1998). EDD has a 
reported role in the DNA damage response and has been implicated in the S 
phase and G2/M DNA damage checkpoints (Henderson, Russell et al. 2002, 
Munoz, Saunders et al. 2007, Gudjonsson, Altmeyer et al. 2012). EDD enhances 
activation of the DNA damage response kinase Chk2 in response to ionizing 
radiation or the radiomimetic phleomycin (Henderson, Munoz et al. 2006).  
While low in benign tissue and borderline ovarian  tumors, EDD is 
overexpressed in 47% of all types of ovarian cancer and 73% of serous ovarian 
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tumors (Clancy, Henderson et al. 2003). The EDD protein is also overexpressed 
or mutated in several solid tumors including breast, hepatocellular, tongue, 
gastric, and melanoma (Mori, Sato et al. 2002, Clancy, Henderson et al. 2003, 
Fuja, Lin et al. 2004). EDD is also associated with a 2-fold increased risk of 
recurrence and death in patients that initially responded to chemotherapy 
(O'Brien, Davies et al. 2008). The edd gene is on chromosome 8q22.3 and 
amplification of this chromosomal region is associated with cisplatin resistance 
(Wasenius, Jekunen et al. 1997, Callaghan, Russell et al. 1998). Knockdown of 
EDD with small interfering RNA (siRNA) decreased colony formation in A2780-
cp70 ovarian cancer cells, a derivative selected for cisplatin resistance in vitro, 
when co-treated with cisplatin (O'Brien, Davies et al. 2008). Collectively, these 
results suggest that EDD may play a role in tumor maintenance and/or cisplatin 
resistance.  
Altered expression of many genes and proteins is reported in tumor tissue 
and in isogenic cell lines that have been selected for cisplatin resistance. 
However, many of these studies failed to demonstrate that changes in 
expression of a particular protein were sufficient to induce cisplatin resistance, 
raising the possibility that the observed overexpression of EDD in ovarian tumors 
may not be directly responsible for acquired cisplatin resistance. These results 
show that EDD directly contributes to cisplatin resistance through its E3 ubiquitin 
ligase activity in ovarian cancer cells and provides evidence for EDD as a 




Materials and Methods 
 
Cell lines and antibodies 
ES-2 cells were from Runzhao Li, A2780ip2 cells were from Charles Landen, and 
OVCAR5 cells were from Thomas Hamilton.COS-7 cells were from American 
Type Culture Collection (ATCC, Manassas, VA). Stable EDD shRNA cells were 
generated by retroviral transduction: control shRNA (5′GCTGCAAGACCA 
TACACTTAT), EDD-shRNA1 (5′GCTGTAGATTTCAACTTAGAT), EDD-shRNA2 
(5′GCCATTAGAAAGAACCACAAA) and EDD-shRNA3 (5′TGACAGCAGAACA 
ACATAATT). Puromycin-resistant clones (ES-2 and A2780ip2) or populations 
(OVCAR5) were selected. Cisplatin was from Sigma–Aldrich (St Louis, MO). 
Poly(ADP-ribose) polymerase (PARP) antibody was from Cell Signaling and the 
EDD (M19) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). 
Lipofectamine 2000 (Invitrogen) was used for transfections, according to the 
manufacturer’s protocol. 
siRNA transfection 
Cell lines were transfected with 45 nmol of control or EDD siRNA (Sigma–
Aldrich). siRNA1: SASI_Hs01_00175227 (5′CCAUUUACCCUGGCUAGUA); 
siRNA2: SASI_Hs02_00348492 (5′GCGACUCUCCAUGGUUUCU). Control 
siRNA was Universal Negative Control #1 (Sigma–Aldrich).  
Western blotting 
Floating and adherent cells were lysed with M2 lysis buffer containing 0.5% 
sodium dodecyl sulfate (Eblen, Catling et al. 2001). Typically, 65 µg of protein 
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lysate was separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (7–12% gradient gel) and immunoblotted proteins were 
visualized using enhanced chemiluminescence (Pierce).  
Crystal violet staining 
Cells were fixed with 4% paraformaldehyde, stained with 0.05% crystal violet in 
2% ethanol for 15 min, washed five times with phosphate-buffered saline and 
dried. Stained cells were solubilized with 2% sodium dodecyl sulfate in 
phosphate-buffered saline and absorbance was measured at 550 nm.  
Flow cytometry 
Floating and adherent cells were fixed in ethanol and stained with propidium 
iodide (Molecular Probes, Eugene, OR). DNA content was determined by flow 
cytometry and sub-2n cells were counted as apoptotic. The Student’s t-test was 
performed on three independent experiments done in duplicate.  
MTS assay 
Stable ES-2 shRNA cell lines were plated in quadruplicate onto 96-well dishes 
and treated with cisplatin or saline for 72 h. MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent (Promega, 
Madison, WI) was added for the last 2hr and absorbance measured. The results 
are a combination of three independent experiments.  
Apoptosis assay 
COS-7 cells on coverslips were transfected with 2 µg of Flag-EDD, Flag-EDD-
C2768A or green florescent protein (GFP). After 24 h, the cells were treated with 
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cisplatin for 24hr and fixed with 4% paraformaldehyde. Apoptotic cells were 
labeled using the TACS® 2 Tdt-Blue Label In Situ Apoptosis Detection Kit 
(Trevigen, Gaithersburg, MD). Flag-EDD-transfected cells were immunostained 
with M2 anti-Flag antibody (Sigma–Aldrich), followed by fluorescein 
isothiocyanate-labeled secondary antibody (Jackson ImmunoResearch, West 
Grove, PA). At least 500 transfected cells per coverslip were counted and the 
percentage of transfected apoptotic cells was determined. Four independent 
experiments were performed for the cisplatin dose experiment. For the EDD-
C2768A experiment, three independent experiments were performed comparing 
GFP, EDD, and EDD-C2768A at a single dose of 15 µM cisplatin. The data for 
GFP compared with EDD included the data from the 15 µM group in the cisplatin 
dose experiment, for an n = 7. Two-sample t-tests were conducted to determine 
significance.  
Intraperitoneal ovarian cancer model and in vivo delivery of siRNA  
Female athymic nude mice (NCr-nu) were purchased from the National Cancer 
Institute (Frederick, MD) after Institutional Animal Care and Use Committee 
approval of protocols and cared for in accordance with guidelines of the 
American Association for Accreditation of Laboratory Animal Care. ES-2 and 
A2780ip2 cells were suspended in serum-free Hanks' balanced salt solution at a 
concentration of 5 × 106 cells/ml, and 1 × 106 cells were injected intraperitoneally 
in 200 µl into 40 mice per experiment. After 1 week, mice (n = 10 per group) were 
randomized to treatment with (i) 5 µg control siRNA (sense sequence: 5′-
UUCUCCGAACGUGUCACGU-3′, Sigma) in 1,2-dioleoyl-sn-glycero-3-
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phophatidylcholine (DOPC), (ii) 5 µg anti-human EDD siRNA (Sigma product 
SASI_Hs01_00175227), (iii) 5 µg control siRNA plus cisplatin or (iv) 5 µg EDD-
targeting siRNA in DOPC plus cisplatin. siRNA constructs were incorporated in 
DOPC nanoparticles (DOPC) as described previously (Landen, Kinch et al. 2005, 
Landen, Merritt et al. 2006) and the lyophilized product was stored at −4°C for <4 
weeks. Prior to treatment, the siRNA/DOPC complex was reconstituted in 0.9% 
saline and administered intraperitoneally twice per week in a volume of 100 µl. 
Cisplatin was administered intraperitoneally at a dose of 40 µg weekly. Mice were 
treated for 4 weeks before killing and tumor collection. Tumors were excised and 
total tumor weight recorded. Statistical analysis comparisons of tumor weights 
were made using a two-tailed Student’s t-test, if assumptions of data normality 
were met. Those represented by alternate distribution were examined using a 
non-parametric Mann–Whitney U-test. Differences between groups were 
considered statistically significant at P < 0.05. Error bars represent standard 
error. Number of mice per group (n = 10) was chosen as directed by a power 
analysis to detect a 50% decrease in tumor growth with beta error of 0.2. 





EDD knockdown increases cisplatin sensitivity 
O’Brien et al. showed that EDD siRNA reduced colony formation after 
cisplatin treatment in the cisplatin-resistant A2780-cp70 cell line (O'Brien, Davies 
et al. 2008). However, although 72hr cisplatin treatment induced dose-dependent 
cell death in ES-2 and A2780ip2 cells transfected with control siRNA (Figure 
3.1A and B), the catastrophic apoptosis induced by EDD siRNA obscured any 
cisplatin effect. At 24hr of cotreatment, EDD knockdown in ES-2 cells conferred 
cisplatin sensitivity (Figure 3.1C), whereas the strong apoptotic response of EDD 
knockdown alone in A2780ip2 cells masked any potential effects on cisplatin 
sensitization (Figure 3.1D). Although EDD knockdown induced apoptosis in 
A2780-cp20 cisplatin-resistant cells, it did not enhance cell death in response to 
cisplatin in these cells (Figure 3.1E).  
In order to separate the basic cell survival function of EDD from a potential 
role in cisplatin resistance, we generated ES-2 (Figure 3.2A), A2780ip2 (Figure 
3.2B) and OVCAR5 (Figure 3.2C) cell lines with constitutive knockdown of EDD 
using retroviral transduction of three separate shRNAs. These cells represent the 
small portion of the population that can survive initial EDD knockdown, as the 
majority of the cells undergo apoptosis. Immunoblotting showed that these pools 
of cells survive because they are not dependent upon EDD for Mcl-1 expression 
(Figure 3.3). Cellular clones of ES-2 and A2780ip2 cells and a population of 
OVCAR5 cells were selected. MTS assays demonstrated that ES-2 clones 
expressing EDD shRNA were 4- to 21-fold more sensitive to cisplatin than cells 
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expressing control shRNA, with EC50 values of 48.8 µM for the control-1 (clone 1) 
shRNA line, 12.0 µM for EDD shRNA1, 7.4 µM for EDD shRNA2, and 2.3 µM for 
the EDD shRNA3 cell lines (Figure 3.2D). In addition, A2780ip2 (Figure 3.2E) 
and OVCAR5 (Figure 3.2F) EDD shRNA cells were more sensitive to cisplatin 
after 24hr of treatment compared with the control shRNA cells, as measured by 
increased induction of PARP cleavage. These results demonstrate that stable 












Figure 3.1.  Transient EDD knockdown may sensitize cells to cisplatin. (A) ES-2 
and (B) A2780ip2 cells were transfected with either control siRNA or EDD 
siRNA1 and immediately treated with vehicle, 0.3, 1, or 3 µM cisplatin for 72hr. 
Photographs were taken at 10X magnification. (C) ES-2 and (D) A2780ip2 cells 
were either untreated (None) or transfected with either control siRNA or EDD 
siRNA1. Cells were treated with Vehicle (Veh), 1, or 5 µM cisplatin immediately 
after transfection and harvested at 24hr for immunoblotting. (E) Apoptosis is 
induced in cisplatin resistant cells upon EDD knockdown. A2780 and the 
cisplatin-resistant A2780-cp20 cell line were transfected with control siRNA or 
EDD siRNA1 and then treated with increasing amounts of cisplatin. Cells were 










Figure 3.2. Stable EDD knockdown increases cisplatin sensitivity. (A) ES-2, (B) 
A2780ip2 and (C) OVCAR5 cells were retrovirally transduced with control or one 
of three EDD shRNAs and clones (ES-2 and A2780ip2) or populations 
(OVCAR5) were selected. Cell lysates were immunoblotted for EDD expression. 
Multiple clones from the same shRNA are designated as A or B. (D) ES-2 control 
shRNA or EDD shRNA cells were treated with cisplatin for 72h and cell viability 
measured by MTS assay. Percent survival was plotted against the log of the 
cisplatin concentration. The results are from three independent experiments 
performed in quadruplicate. (E) A2780ip2 and (F) OVCAR5 shRNA cells were 
treated with cisplatin for 24hr and cell lysates from floating and adherent cells 
were immunoblotted for EDD and PARP cleavage. The numbers underneath the 
blot represent the relative intensity of cleaved PARP in each lane compared with 







Figure 3.3.  Normal Mcl-1 expression in EDD stable knockdowns. A2780ip2, ES-







EDD is sufficient to induce cisplatin resistance 
To determine if EDD is sufficient to induce cisplatin resistance, COS-7 
cells were transfected with Flag-EDD or GFP for 24hr and then treated with 
cisplatin for an additional 24hr. Cells were immunostained for Flag-EDD and 
costained with the TACS® 2 Tdt-Blue Label In Situ Apoptosis Detection Kit, 
staining apoptotic nuclei black under brightfield microscopy (Figure 3.4A). The 
percentage of transfected cells that were apoptotic after cisplatin treatment was 
determined by counting. Cells transfected with Flag-EDD had significantly less 
apoptosis at the higher cisplatin doses of 15 µM (GFP = 8.9%, EDD = 4.0%, P < 
0.03) and 30 µM (GFP = 14.6%, EDD = 6.0%, P < 0.02) compared with the GFP-
transfected cells, demonstrating that EDD overexpression was sufficient to 
induce cisplatin resistance (Figure 3.5A). To determine if EDD ubiquitin ligase 
activity was required, cells were transfected with GFP, Flag-EDD, or Flag-EDD-
C2768A, a ubiquitin ligase-deficient mutant, and treated with 15 µM cisplatin for 
24hr. EDD-C2768A did not induce cisplatin resistance compared with the GFP 
control, whereas EDD caused 2.4-fold protection (GFP = 9.4%, EDD = 3.8%, 
EDD-C2768A = 11.8%) (Figure 3.5B). Statistical significance was seen between 
EDD and GFP, and EDD and EDD-C2768A. These results show that EDD-
induced cisplatin resistance is dependent upon its E3 ubiquitin ligase activity. 
EDD localizes to the nucleus, where cisplatin induces DNA damage, and 
mutation of EDD at Cys2768 did not affect nuclear localization (Figure 3.4B) 






Figure 3.4. EDD overexpression in apoptosis assay and EDD localization. (A) 
COS-7 cells plated on coverslips were transfected with Flag-EDD (24hr) and then 
treated with cisplatin for an additional 24hr. Cells were fixed and stained for the 
transfected gene (green) and apoptotic (black) cells and DAPI (blue). (B) EDD 
mutation does not affect nuclear localization. COS-7 cells on coverslips were 
transfected with either Flag-EDD or Flag-EDD-C2768A. The cells were then fixed 
and immunostained with anti-Flag antibody followed by FITC-labeled secondary 





Figure 3.5. EDD overexpression is sufficient to induce cisplatin resistance, 
dependent upon its ubiquitin ligase activity. (A) COS-7 cells on coverslips were 
transfected with Flag-EDD or GFP for 24hr and then treated with cisplatin for an 
additional 24hr. Fixed cells were stained for transfected and apoptotic cells and 
4′,6-diamidino-2-phenylindole stained, as shown in Figure 3.4. The percentage of 
apoptotic transfected cells was determined by cell counting. At least 500 cells 
were counted per condition in each of four experiments. (B) Same as in (A), but 
cells were transfected with GFP, Flag-EDD or Flag-EDD-C2768A, an ubiquitin 
ligase-deficient mutant. Cells were treated with 15 µM cisplatin for 24hr on the 
day following transfection and the percentage of apoptotic transfected cells was 
determined by cell counting 24hr later. 
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EDD knockdown in vivo enhances cisplatin efficacy  
Charles Landen, Jr. and Anil Sood have previously demonstrated in vivo 
delivery of siRNA to ovarian tumors via DOPC liposomal nanoparticles, resulting 
in knockdown of the target protein and a reduction in tumor burden (Landen, 
Kinch et al. 2005, Halder, Kamat et al. 2006, Landen, Merritt et al. 2006, Lin, 
Immaneni et al. 2008, Merritt, Lin et al. 2008, Mangala, Han et al. 2009, 
Chakravarty, Roy et al. 2011, Nick, Stone et al. 2011). To determine if EDD is a 
viable target for the treatment of ovarian cancer, we generated intraperitoneal 
xenografts of ES-2 and A2780ip2 cells in female athymic nude mice. One week 
later, 10 mice per group were treated intraperitoneally twice per week with either 
control or EDD siRNA1 in DOPC liposomes, in combination with either cisplatin 
or saline treatment once weekly. After 4 weeks, mice were killed and tumor 
tissue was harvested. When compared to control siRNA treatment alone, 
cisplatin combined with control siRNA/DOPC showed a trend toward significance 
in ES-2 xenografts when measuring tumor weight (37.7% reduction, P = 0.167) 
but became statistically significant when cisplatin was combined with EDD 
siRNA1/DOPC (77.9% reduction, P = 0.004) (Figure 3.6A). In A2780ip2 
xenografts, cisplatin plus control siRNA/DOPC treatment was not significantly 
different compared with control siRNA/DOPC alone (39.2% reduction, P = 0.349), 
but cisplatin plus EDD siRNA1/DOPC was significantly better than control 
siRNA/DOPC alone (75.9% reduction, P = 0.042). In those mice treated with 
cisplatin, cotreatment with EDD siRNA1/DOPC was significantly better than co-
treatment with control siRNA/DOPC in ES-2 (64% reduction, P = 0.035) and 
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showed a trend toward significance in A2780ip2 (60.3% reduction, P = 0.168). 
Immunohistochemistry of A2780ip2 tumors with EDD antibody showed EDD 
expression in tumors treated with control siRNA, with a possible enhancement of 
EDD expression in tumors following cisplatin treatment (Figure 3.6B and C). EDD 
siRNA1 treatment in vivo decreased EDD expression in tumors (Figure 3.6D and 
E). Collectively, these results suggest that therapies targeting EDD expression 









Figure 3.6 . DOPC nanoparticle delivery of EDD siRNA in vivo reduces tumor 
burden. (A) ES-2 or A2780ip2 cells were injected intraperitoneally into 40 female 
athymic nude mice per cell line. Mice were either treated with control siRNA in 
DOPC (lane 1), EDD siRNA1 in DOPC (lane 2), control siRNA in DOPC plus 
cisplatin (lane 3), or EDD siRNA1 in DOPC plus cisplatin (lane 4). Mice were 
treated for 4 weeks before killing and tumor collection. Tumors were excised and 
total tumor weight determined. The number above each lane represents the 
mean tumor weight in grams. Immunohistochemistry demonstrates EDD 
knockdown in vivo. A2780ip2 tumors from mice treated with (B) control siRNA in 
DOPC, (C) control siRNA in DOPC plus cisplatin, (D) EDD siRNA1 in DOPC and 
(E) EDD siRNA1 in DOPC plus cisplatin were immunostained with EDD antibody 







These results show that EDD directly regulates cisplatin sensitivity. A 
previous study has shown that EDD overexpression correlates with poor survival 
for patients with recurrent ovarian cancer and that knockdown of EDD with siRNA 
in cisplatin-resistant A2780-cp70 cells decreases colony formation by 40% after 
cisplatin treatment (O'Brien, Davies et al. 2008). However, a portion of this effect 
may be due to the cell survival functions of EDD described in the previous 
chapter. To separate these functions, we generated stable knockdown cells to 
select for those cells that could survive initial EDD knockdown. These cells 
showed normal levels of Mcl-1, demonstrating that this small portion of the initial 
cell population was not dependent upon EDD for Mcl-1 expression. By separating 
these functions, we demonstrated that loss of EDD sensitizes cells to cisplatin. 
Expression of EDD in ovarian cancer cell lines does not directly correlate with 
reported cisplatin sensitivity, as some ovarian cancer cell lines with high EDD 
expression have low cisplatin IC50s and some of those with higher resistance 
express lower levels of EDD (Figure 2.1 and Table 3.1) (Smith, Ngo et al. 2005, 
Matsumura, Huang et al. 2011, Ye, Fu et al. 2011, Saran, Arfuso et al. 2012). 
This is likely due to the multiple mechanisms of cisplatin resistance in cells and 
tumors (Galluzzi, Senovilla et al. 2012). Indeed, A2780-cp70 cells selected in 
vitro for cisplatin resistance after long-term exposure did not have higher levels of 
EDD expression than parental A2780 cells (O'Brien, Davies et al. 2008). 
Importantly, we show that overexpression of EDD was sufficient to induce 
resistance to cisplatin and was dependent upon EDD ubiquitin ligase activity. 
89 
 
EDD has been suggested to play a role in the DNA damage response, 
particularly in response to double strand breaks. EDD and the E3 ubiquitin ligase 
TRIP12 regulate levels of RNF168, a regulator of histone ubiquitination after 
DNA damage, resulting in controlled spread of histone ubiquitination from the 
area of double strand breaks (Gudjonsson, Altmeyer et al. 2012); however, no 
reports have linked RNF168 to cisplatin resistance. EDD is important in activation 
of the DNA damage response kinase Chk2, as EDD-depleted cells show reduced 
activation of Chk2 in response to double strand breaks (Henderson, Munoz et al. 
2006). EDD knockdown increased sensitivity of HeLa cells to phleomycin, 
regulating both the S phase and the G2/M phase checkpoints in treated cells 
(Henderson, Munoz et al. 2006, Munoz, Saunders et al. 2007, Benavides, Chow-
Tsang et al. 2013). In the presence of DNA damage, EDD knockdown cells 
underwent radio-resistant DNA synthesis and premature entry into mitosis, 
leading to mitotic catastrophe (Munoz, Saunders et al. 2007).  
Both Bcl-xL and Mcl-1 have been implicated to protect ovarian cancer 
cells from chemotherapy-induced apoptosis, suggesting that EDD upregulation of 
Mcl-1 expression (as described in the previous chapter) may also contribute to 
cisplatin resistance; however, the requirement for ubiquitin ligase activity for 
cisplatin resistance, but not for induction of the Mcl-1 promoter, strongly suggests 
that the regulation of Mcl-1 by EDD is distinct from the induction of cisplatin 
resistance as illustrated in Figure 3.7 (Simonin, Brotin et al. 2009). Interestingly, 
EDD itself appeared to be upregulated in xenografts from mice treated with 
cisplatin, which may be clinically important in regards to a study showing EDD 
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overexpression in recurrent ovarian tumors from patients who had a favorable 
response to initial chemotherapy (O'Brien, Davies et al. 2008).  
Small molecule inhibitors of ubiquitin ligases have had little success due to 
the lack of a defined catalytic domain and the utilization of protein–protein 
interactions in order to ubiquitinate targets. Charles Landen, Jr. and Anil Sood 
have previously demonstrated that DOPC nanoparticles can be utilized to 
efficiently deliver siRNA to ovarian tumor tissue to inhibit tumor growth and 
metastasis and to enhance chemosensitivity (Landen, Kinch et al. 2005, Halder, 
Kamat et al. 2006, Landen, Merritt et al. 2006, Lin, Immaneni et al. 2008, Merritt, 
Lin et al. 2008, Mangala, Han et al. 2009, Chakravarty, Roy et al. 2011, Nick, 
Stone et al. 2011). Our in vivo data demonstrated that EDD is a valid target for 
treating epithelial ovarian cancer in combination with chemotherapy. EDD siRNA 
showed enhanced efficacy over cisplatin treatment alone in ES-2 xenografts and 
a trend toward significance in A2780ip2 xenografts. This effect of EDD siRNA 
was likely due to both the positive effects of EDD on cell survival and the 
enhancement of cisplatin resistance. Upon knockdown in vivo, loss of EDD likely 
enhances both cell death and cisplatin sensitivity. Our findings that EDD 
regulates survival Mcl-1 regulation independent of its ubiquitin ligase activity and 
cisplatin resistance through its ubiquitin ligase domain suggest that therapies 
targeting EDD expression, such as EDD siRNA in nanoparticles, may prove to be 
a more beneficial therapeutic approach than a chemical inhibitor of EDD ubiquitin 
ligase activity, although the latter alone may have some beneficial role in 





Figure 3.7.  Model for EDD regulation of survival and cisplatin resistance. EDD 
enhances cell survival by promoting Mcl-1 transcriptional expression through 
regulation of an unknown transcription factor (TF). Enhancement of Mcl-1 protein 
expression is independent of GSK-3β inhibition of Mcl-1 protein levels. EDD also 














IOSE 3.17 (Saran, Arfuso et al. 2012) 
A2780 1.74 (Matsumura, Huang et al. 2011) 
ES-2 48.8 (Bradley, Zheng et al. 2014) 
OV2008 1.72 (Ye, Fu et al. 2011) 
OVCAR3 25.7 (Smith, Ngo et al. 2005) 
OVCAR5 5.02 (Matsumura, Huang et al. 2011) 
SKOV-3 21.7 (Smith, Ngo et al. 2005) 
TOV-21G 18.5 (Smith, Ngo et al. 2005) 
 
Table 3.1.  Cisplatin sensitivities across ovarian cancer cell lines. The reported 
IC50 to cisplatin of the cell lines used in this study and the references they are 
















 Oral squamous cell carcinoma is diagnosed in more than 40,000 
Americans each year, with 20% of these patients ultimately dying from this 
disease (Siegel, Naishadham et al. 2013). Oral cancer is of primary concern 
worldwide since it affects over 330,000 people each year with 54% of these 
patients eventually dying from this type of cancer (Parkin, Bray et al. 2005). Even 
though most oral squamous cell carcinomas remain localized, some patients 
experience metastasis to the lymph nodes, which is often difficult to treat even 
after surgery and radiation. To combat this issue, patients with metastasis are 
typically treated with chemotherapeutic drugs such as cisplatin, paclitaxel, and 5-
fluorouracil. Drug resistance in this type of carcinoma is a reality, but is not highly 
studied.  
 The E3 ubiquitin ligase EDD is genetically amplified in 50% of oral 
squamous cell carcinomas of the tongue (Clancy, Henderson et al. 2003). This is 
similar to ovarian cancer where edd is upregulated in 47% of ovarian cancers 
(73% of serous ovarian cancers) and this cancer is also commonly treated with 
cisplatin often leading to drug resistance (Clancy, Henderson et al. 2003). My 
previous research in ovarian cancer demonstrated that EDD is sufficient to 
promote cisplatin resistance in ovarian cancer, which is dependent on its 
ubiquitin ligase activity, as described in Chapter 3 and in my recent publication 
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(Bradley, Zheng et al. 2014). Based on this research, this led me to hypothesize 
that EDD may also be involved in mediating cisplatin resistance in oral squamous 
cell carcinoma since both oral cancer and ovarian cancers are treated with 
cisplatin and edd is upregulated in both.  
 EDD ubiquitinates several proteins to regulate their degradation (TopBP1, 
Paip2, Katanin p60, TERT, and RNF168) or stability (βcatenin) (Honda, Tojo et 
al. 2002, Yoshida, Yoshida et al. 2006, Maddika and Chen 2009, Gudjonsson, 
Altmeyer et al. 2012, Jung, Wang et al. 2013, Okamoto, Bartocci et al. 2013). It is 
uncertain at this time which known or unknown ubiquitination targets of EDD are 
involved in regulating cisplatin resistance in ovarian cancer. Although a 
connection has not been established between EDD and oral squamous cell 
carcinoma, overexpression of EDD is correlated with a two-fold increased risk of 
disease recurrence in ovarian cancer patients that initially responded to 
chemotherapeutic treatment (O'Brien, Davies et al. 2008). My aim is to establish 
a connection between EDD and oral squamous cell carcinoma to determine if 
EDD regulates cisplatin sensitivity in these cells as well as to determine the 




Materials and Methods 
Cell lines and antibodies 
IOSE cells were from Nelly Auersperg. HeLa and SKOV-3 cells were from 
American Type Culture Collection (ATCC, Manassas, VA). UM-SCC-9 and UM-
SCC-25 cell lines were obtained from Steve Rosenzweig (MUSC). UM-SCC-11A, 
UM-SCC-11B, UM-SCC-22B, and UM-SCC-74B cells were from Viswanathan 
(Visu) Palanisamy (MUSC). Inducible stable EDD knockdown cell lines were 
generated by retroviral transduction with pTRIPZ shRNA (Thermo Scientific, 
Waltham, MA): Scrambled control (RHS4743), EDD-shRNA1 (V2THS_202102, 
5’TAGAGGAATAGAGTGGGAC), EDD-shRNA2 (V2THS_203176, 5’TTGGAA 
TCTACATTCACTG), EDD-shRNA3 (V2THS_75176, 5’TTATTAAAGAATGCAC 
ACC). Initial transfection of 3µg shRNA plasmid, 3µg ∆8.91, and 1.5µg pVSV-G 
were performed with calcium phosphate transfection according to the 
manufacturer’s protocol (Clontech, Mountain View, CA).   Stable populations 
were selected with puromycin and shRNA expression was induced with 
doxycycline (Sigma-Aldrich, St Louis, MO). Non-inducible stable EDD shRNA 
cells were generated by retroviral transduction: control shRNA 
(5′GCTGCAAGACCATACACTTAT), EDD-HP1 (5′GCTGTAGATTTCAACT 
TAGAT), EDD-HP2 (5′GCCATTAGAAAGAACCACAAA) and EDD-UTR 
(5′TGACAGCAGAACAACATAATT). Puromycin-resistant populations were 
selected. Cisplatin was from Sigma–Aldrich (St Louis, MO). Poly (ADP-ribose) 
polymerase (PARP) antibody was from Cell Signaling and the EDD (M19) 




Cell lines were transfected with 45 nmol of control or EDD siRNA (Sigma–
Aldrich). siRNA1: SASI_Hs01_00175227 (5′CCAUUUACCCUGGCUAGUA); 
siRNA2: SASI_Hs02_00348492 (5′GCGACUCUCCAUGGUUUCU). Control 
siRNA was Universal Negative Control #1 (Sigma–Aldrich).  
Western blotting 
Floating and adherent cells were lysed with M2 lysis buffer containing 0.5% 
sodium dodecyl sulfate (Eblen, Catling et al. 2001). Typically, 65 µg of protein 
lysate was separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (7–12% gradient gel) and immunoblotted proteins were 
visualized using enhanced chemiluminescence (Pierce).  
Fluorescence Activated Cell Sorting 
Inducible stable EDD knockdown cell lines utilize pTRIPZ shRNA which 
expresses red fluorescent protein (RFP). Cells were sorted for the top 25% of 
cells expressing the highest levels of RFP. Cells were treated with doxycycline 
(0.5µg/mL) daily for one week. Cells (5x106) were trypsinized, centrifuged at 
1500rpm for 5 minutes, washed with 1xPBS, and centrifuged again. Cells were 
resuspended in 1mL PBS and 1µL of violet LiveDead (Invitrogen) was added, 
cells incubated on ice for 30 minutes in the dark. Cells were then centrifuged, 
washed with PBS, centrifuged, and resuspended in 500uL Cell Staining Buffer 
(PBS + 1%BSA). Finally, cells were filtered through 40uM capped FACS tubes 
(BD 352235, BD Biosciences, San Jose, CA) just before being sorted on the 
FACS Aria Iiu Cell Sorter in the Flow Cytometry core at MUSC at RFP 
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wavelength (553-574nm) and LiveDead violet (405 to 451nm). Cells were sorted 
into media +50% FBS +Pen/Strep antibiotic and kept on ice until being 
centrifuged, resuspended in media +10% FBS +Pen/Strep +doxycycline 
+puromycin, and plated.   
Colony Formation Assay 
One thousand cells were plated on a 35mm dish. The following day, cells were 
treated with cisplatin for 2 hours, washed with PBS, and incubated with fresh 
media +10% FBS for 3-7 days. Cells were collected by being washed twice with 
PBS and fixed with 4% paraformaldehyde for 20 minutes at room temperature, 
washed with PBS, stained with 0.05% crystal violet in 2% ethanol for 15 min, 
washed five times with phosphate-buffered saline, and dried. Pictures were taken 
of the plates and colonies were counted either manually or with the GelCount 
Colony Counter (Oxford Optronix, Abingdon, United Kingdom). Stained cells 
were solubilized with 2% sodium dodecyl sulfate in phosphate-buffered saline 
and absorbance was measured at 550 nm. For proliferation assays, cells were 
collected daily for one week without exposure to cisplatin, stained with crystal 
violet, and solubilized in 2% SDS as described above. 
MTS assay 
Stable ES-2 shRNA cell lines were plated in quadruplicate onto 96-well dishes 
and treated with cisplatin or saline for 72hr. MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent (Promega, 
Madison, WI) was added for the last 2hr and absorbance measured. The results 




Transient knockdown of EDD causes apoptosis in oral  squamous cell 
carcinoma cell lines 
 Based on research from Clancy et al., edd is upregulated in 50% of oral 
squamous cell carcinomas of the tongue (Clancy, Henderson et al. 2003). To 
determine EDD protein expression in oral squamous cell carcinomas, cell lysates 
were collected from five different oral squamous cell carcinoma cell lines and 
compared to protein expression in SKOV3, an ovarian cancer cell line, and IOSE, 
an immortalized ovarian surface epithelium cell line as shown in Figure 4.1A. 
While IOSE represents a benign ovarian cell line, a benign oral cell line was not 
available for comparison. The UM-SCC-9 cell line is a squamous cell carcinoma 
of the anterior tongue from a 25 year old male. UM-SCC-25 cells are cells from a 
neck metastasis that initiated in the larynx of a 70 year old male. UM-SCC-11A 
cells are from an epiglottis tumor in a male, while UM-SCC-11B cells are from a 
cervical lymph node tumor that formed from this primary tumor. UM-SCC-74A 
cells were isolated from a tumor at the base of the tongue from a male patient. 
UM-SCC-74B cells were isolated from the larynx as the metastatic tumor cells 
from UM-74A cells (Brenner, Graham et al. 2010). The EDD protein is highly 
expressed in the oral squamous cell carcinoma cell lines analyzed in comparison 
to the ovarian cell lines (Figure 4.1A). To establish if EDD is essential in these 
cell lines, cells were transfected with control siRNA or one of two different EDD 
siRNAs to knockdown EDD expression. EDD siRNA1 has the best ability to 
knockdown EDD protein expression and was found in UM11B and UM74B cell 
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lines to promote apoptosis, as indicated by the cleavage of the PARP protein 
(Figure 4.1B). As seen in ovarian cancer cells, as described in Chapter 2, EDD 
knockdown causes a decrease in the protein expression of the anti-apoptotic 
protein Mcl-1 as well, which mediates apoptosis in these cells. Apoptosis can 
occur in as little as 48 hours after transient EDD knockdown in UM74B cells 
(Figure 4.1C).  
 Repeating this experiment with transient knockdown of EDD with siRNA 
using EDD siRNA1 in SCC9, SCC25, UM11A, UM11B, and UM74B cells, we 
demonstrated that knockdown of EDD causes apoptosis in SCC25 and UM11B 
cell lines as shown in Figure 4.1D. As in Figure 4.1B, EDD transient knockdown 
does not cause apoptosis in UM11A cells. In this experiment, UM74B cells did 
not undergo efficient knockdown of EDD protein, so a conclusion about 
sensitivity to EDD knockdown induced apoptosis cannot be made. Changes in 
Mcl-1 protein expression as a result of EDD knockdown were not consistent, in 
contrast to those changes seen in Figure 4.1B&C. This indicates that the anti-
apoptotic protein Mcl-1 may not be required for mediating cellular survival in all 
oral squamous cell carcinoma cell lines. SCC9 cells, like UM11A cells, are not 
sensitive to EDD knockdown induced apoptosis implying that not all of these oral 
squamous cell carcinoma cell lines utilize the same cell signaling pathways to 








Figure 4.1. SiRNA mediated EDD knockdown causes apoptosis in some oral 
squamous cell carcinoma cell lines. (A) Cell lysates from a benign ovarian cell 
line (IOSE), ovarian cancer cell line (SKOV3), and five different oral squamous 
cell carcinomas were immunoblotted to detect EDD protein expression. (B) 
UM11A, UM11B, and UM74B cell lines were transfected with control siRNA or 
two different siRNAs targeting EDD for 72 hours. Cell lysates were collected and 
blotted for EDD to detect knockdown, PARP to detect apoptosis indicated by the 
presence of a lower, cleaved band of PARP, the anti-apoptotic protein Mcl-1, and 
Actin for a loading control. (C) UM74B cells were transfected with control siRNA, 
EDD siRNA 1, or EDD siRNA 2 for 48 hours. Cell lysates were immunoblotted for 
EDD, PARP to detect apoptosis, Mcl-1, and Actin. (D) SCC9, SCC25, UM11A, 
UM11B, and UM74B cells were transfected with control or EDD siRNA 1 for 72 





Transient knockdown of EDD with siRNA increases cis platin sensitivity in 
some oral squamous cell carcinoma cell lines 
 Based on my research (Bradley, Zheng et al. 2014) and that of O’Brien et 
al. (O'Brien, Davies et al. 2008) in ovarian cancer, which demonstrates that EDD 
knockdown can increase cisplatin sensitivity, I sought to determine if the same 
was true in oral squamous cell carcinoma. Five different oral squamous cell 
carcinoma cell lines (SCC9, SCC25, UM11A, UM11B, and UM74B cells) were 
transfected with EDD siRNA 1 for 24 hours to knockdown EDD protein 
expression (Figure 4.2). Then cells were also treated with a 10 µM dose of 
cisplatin for an additional 24 hours. An increase in cell death, and therefore an 
increased sensitivity to cisplatin treatment, was determined by the relative 
amount of PARP cleavage in comparison to EDD siRNA only treated cells or 
control siRNA plus cisplatin treatment. In cell lines that demonstrated both a 
good knockdown of EDD and were sensitive to EDD knockdown induced 
apoptosis, such as SCC9, SCC25, and UM11B cells, there was also an increase 
in cisplatin sensitivity. In SCC9 and SCC25 cells, this is demonstrated by both a 
decrease in total uncleaved PARP and a slight increase in cleaved PARP. While 
these cell lines are sensitive to both EDD knockdown induced apoptosis and 
cisplatin treatment, the combination of the two demonstrates a further increase in 
cell death.  
 In UM11B cells, which are again sensitive to both apoptosis from EDD 
knockdown and cisplatin, the combination of the two treatments increases 
apoptosis as evidenced by an increase in cleaved PARP. In UM11A cells, as 
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shown in Figure 4.1B & C, these cells are not sensitive to EDD siRNA or 
cisplatin, but the combination of the two treatments does increase apoptosis 
indicating that EDD knockdown may sensitize these cells to cisplatin, whereas 
they were not sensitive previously. In this experiment, the only cell line which 
definitely does not show increased cisplatin sensitivity after EDD knockdown is 
UM74B, but this is due to the fact that there was not a good knockdown of EDD 
after transfection with siRNA. More experiments are needed in this cell line to 
determine if there is an effect of EDD knockdown to increase cisplatin sensitivity. 
Overall, most of the oral squamous cell carcinoma cell lines demonstrated 
increased cisplatin sensitivity as a result of EDD knockdown, including one cell 






Figure 4.2. Transient knockdown of EDD may increase cisplatin sensitivity in 
some oral squamous cell carcinoma cell lines. SCC9, SCC25, UM11A, UM11B, 
and UM74B cell lines were transfected with control siRNA or EDD siRNA1 for 48 
hours and then treated with 10 µM cisplatin for an additional 24 hours. Cell 
lysates were immunoblotted for EDD to show protein knockdown, PARP to 
indicate apoptosis by the cleavage of PARP, the anti-apoptotic protein Mcl-1, and 




Creation of EDD stable knockdown cell lines 
 To further test if EDD knockdown increases cisplatin sensitivity, it is 
essential to separate the functions of EDD in the regulation of cellular survival 
from that in cisplatin resistance. A doxycycline inducible shRNA pTRIPZ plasmid 
was used which encodes either: control shRNA, EDD shRNA 1, EDD shRNA 2, 
or EDD shRNA 3. This plasmid also encodes an RFP (red fluorescent protein) 
expression gene for ease of determining which cells express shRNA. Once a 
stable population that expresses the shRNA plasmid is selected for with 
puromycin, then doxycycline can be used to turn on the shRNA expression to 
knockdown the EDD mRNA and protein expression. This approach also 
addresses whether EDD knockdown with shRNA causes apoptosis in these cell 
lines (UM22B and UM74B) similar to EDD knockdown with siRNA. After the 
addition of doxycycline for at least seven days, RFP expression is visible in a 
high percentage of the cells (about 90% in UM74B and about 60% in UM22B 
cells). EDD shRNA expression does not appear to cause cell death (results not 
shown). Figure 4.3A demonstrates the effectiveness of EDD protein expression 
knockdown after the induction of the EDD shRNA in UM22B cells and Figure 
4.3B displays this in UM74B cells. Based on these results, it seems that EDD 
shRNA 1 and EDD shRNA 3 are the most effective in UM74B and EDD shRNA 3 
causes some knockdown in UM22B cells.  
 In order to obtain a pure population of cells that express the EDD shRNA 
plasmid (as evidenced by RFP expression), FACS was used to sort cells for the 
top 25% of each stable cell lines that express the highest level of RFP. The 
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immunoblot for EDD expression in these stable cell lines is shown in Figure 4.3C, 
where UM22B cells do not have adequate knockdown of EDD, but UM74B cells 
expressing EDD shRNA 3 have an almost complete loss of EDD protein. These 
UM74B cells were tested for cisplatin sensitivity by an MTS assay to evaluate if 
stable knockdown of EDD increases cisplatin sensitivity. Figure 4.3D indicates 
that UM74B EDD shRNA 3 cells are not more sensitive to cisplatin treatment 
over 72 hours than UM74B scrambled shRNA stable cells. Since an MTS assay 
measures the relative amount of living cells by detecting mitochondrial activity, 
this assay may not be the most appropriate way to measure cisplatin sensitivity. 













Figure 4.3. Inducible stable EDD knockdown in oral squamous cell carcinomas. 
(A) UM22B cells were transduced with a lentivirus containing the pTRIPZ plasmid 
which includes either a control shRNA or one of three different EDD shRNAs. 
After selection of a stable population containing the shRNA with puromycin 
selection, shRNA expression in these cells was induced by treatment with 
doxycycline for at least seven days. Cells treated with different doses of 
doxycycline (0, 0.1, or 1 µg/mL) were lysed and immunoblotted for EDD to detect 
knockdown and the anti-apoptotic protein Mcl-1. (B) As in (A), UM74B were 
transduced with control or EDD shRNA and the effectiveness of the knockdown 
is demonstrated in this immunoblot. (C) UM22B and UM74B cells from (A) and 
(B) treated with 1 µg/mL doxycycline for at least one week were sent for FACS 
for RFP expression which is encoded on the pTRIPZ plasmid. The top 25% of 
cells expressing the highest amounts of RFP were selected and cultured. These 
cells were lysed and immunoblotted for EDD to detect knockdown and the anti-
apoptotic protein Mcl-1. (D) UM74B cells from (C) expressing either the control 
shRNA or the EDD shRNA 3 were tested for cisplatin sensitivity by an MTS 
assay over 72 hours. This is a graphical representation of one experiment with 
samples plated in quadruplicate. Absorbance is normalized to the average 






EDD stable knockdown reduces colony size in UM74B c ells 
 Based on results from Figure 4.3D, which indicated that an MTS assay 
may not be the most appropriate way to measure cisplatin sensitivity in the oral 
squamous cell carcinoma cell lines, colony formation assays were used to test 
the EDD stable knockdown cells for relative cisplatin sensitivity. Colony formation 
assays allow for the analysis of the DNA damage response pathway since these 
cells are treated with cisplatin for 2 hours and allowed to repair their DNA over 
several days rather than 72 hours of continuous cisplatin treatment as in an MTS 
assay. UM74B cells, scrambled shRNA or EDD shRNA 3 overexpressing, were 
treated with different concentrations of the chemotherapeutic drug cisplatin (0, 
10, 20, 40 µM) for 2 hours and then allowed to recover for 3 days. After 3 days, 
cells were collected and the amount of colonies remaining on the plate was 
counted (Figure 4.4A). EDD stable knockdown cells (sh3) had slightly fewer 
colonies (approximately 27% less at 20 µM) than control scrambled knockdown 
cells (Figure 4.4A). This is similar to results published by O’Brien et al in A2780-
cp70 cells treated with EDD siRNA and 20 µM cisplatin (O'Brien, Davies et al. 
2008). 
 The colonies from the EDD stable knockdown cells appeared to be much 
smaller than those in the scrambled control cell lines when treated with cisplatin 
(Figure 4.4D). To determine the relative amount of cells on the plate, as 
determined by the total amount of crystal violet staining on the colonies, the 
absorbance of solubilized crystal violet was measured. EDD stable knockdown 
cells had 67% less (at 20 µM) crystal violet staining, and therefore theoretically 
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fewer cells, when treated with cisplatin than the scrambled control cells (Figure 
4.4B). This difference is also evident over six days of recovery time after cisplatin 
treatment as well (Figure 4.4C). Based on these results, it appears that EDD 
stable knockdown in UM74B cells slows cellular proliferation when cells are 









Figure 4.4. UM74B stable EDD knockdown cells demonstrate reduced colony 
size in cisplatin sensitivity colony formation assays. (A) UM74B scrambled 
control shRNA expressing cells and UM74B EDD shRNA3 expressing cells were 
plated sparsely, treated for 2 hours with different concentrations of cisplatin, and 
colonies were allowed to grow for 3 days before being collected and stained with 
crystal violet. The number of colonies was counted and the results from one 
experiment are depicted in this graph. The number of colonies in untreated cells 
is set to 1 and other conditions are normalized to this number of colonies in the 
control. (B) As in (A), after colonies were counted, the crystal violet staining the 
colonies was solubilized with 2% SDS and the absorbance was measured at 550 
nm. Solubilized crystal violet allows for relative quantitation of total crystal violet 
staining taking into account both colony number and colony size. This graph is a 
representation of one experiment and absorbance is normalized to the untreated 
control cells in each cell line. (C) As in (B), colonies from each stable cell line 
were allowed to grow for 3 or 6 days after 2 hours of cisplatin treatment. 
Absorbance of solubilized crystal violet staining is normalized to untreated cells. 
This graph is a representation of a single experiment. (D) Scrambled shRNA 
expressing cells and EDD shRNA3 expressing cells were collected 3 days after 2 
hours of 20 µM cisplatin treatment as in (A). These pictures are used to 
demonstrate the relative number of colonies and size of colonies on each plate 





EDD stable knockdown does not affect proliferation across oral squamous 
cell carcinoma cell lines 
 To resolve whether EDD stable knockdown has an effect on cellular 
proliferation rather than on cisplatin sensitivity, I performed colony formation 
assays over time in untreated cells. In order to have another cell line to compare 
the UM74B EDD stable knockdown cell line, UM22B cells were transduced with 
an EDD shRNA retroviral vector. The UM22B EDD stable knockdown cell line 
expressing the UTR (untranslated region) targeted shRNA showed the greatest 
knockdown of EDD protein expression as compared to the scrambled control 
(Figure 4.5A). A proliferation assay was used to measure colony growth over 7 
days daily in UM22B and UM74B scrambled control shRNA and EDD shRNA 
expressing cells. There was not a significant difference in cellular proliferation in 
the UM22B scrambled and EDD knockdown cell lines over time, but UM74B EDD 
stable knockdown cells did grow 31% slower than their scrambled control 
counterpart at day 7 (Figure 4.5B).  
 In order to verify that the effect seen in the UM74B cells is due to EDD 
knockdown and not a coincidence of the stable cell line population simply having 
a slower rate of proliferation, I performed a proliferation assay with the UM74B 
cells scrambled and EDD knockdown with and without doxycycline. Without 
doxycycline to activate expression of the shRNA in the cells, the shRNA will not 
be expressed and the cells will return to a basal expression of EDD protein. 
Figure 4.5C illustrates that the UM74B cells without doxycycline do not grow 
significantly slower than the populations treated with doxycycline and therefore 
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expressing shRNA (either scrambled or EDD shRNA 3). Comparison of UM74B 
scrambled cells with doxycycline to EDD shRNA 3 cells with doxycycline in this 
experiment shown in Figure 4.5C indicates that EDD stable knockdown cells do 
not have a reduced rate of proliferation in this experiment even though the EDD 
knockdown is still present (results not shown). Due to this inconsistency, more 
experiments are needed to finally determine if EDD stable knockdown does 
indeed reduce proliferation in the UM74B cells. There is not an effect on the 
proliferation in the UM22B cells demonstrating that an effect of EDD knockdown 








Figure 4.5.  UM74B EDD stable knockdown cells show a reduction in 
proliferation. (A) Non-inducible shRNAs, either control or shRNA targeting EDD 
(HP2, HP2, and UTR), were transduced into UM22B and UM74B cells, then 
populations were selected with puromycin. Cell lysates were collected from these 
populations and immunoblotted for EDD to detect protein knockdown. These 
same shRNAs were also used in ovarian cancer cells as described in Chapter 3. 
(B) UM22B scrambled control shRNA and UM22B EDD shRNA UTR cells from 
(A) and UM74B scrambled control shRNA and UM74B EDD shRNA 3 from 
(Figure 4.3C) were used in a colony formation assay. Cells were plated sparsely 
in doxycycline and colonies after a certain number of days from 1-7 were 
collected and stained with crystal violet. Crystal violet staining from each 
experimental plate of cells was solubilized with 2% SDS and absorbance was 
measured at 550nm. Absorbance of each experimental condition was normalized 
to cells from day 1. (C) UM74B scrambled and EDD shRNA 3 expressing cells 
either treated with doxycycline for 7 days prior to the experiment and during the 
experiment were compared to the same cells that were not treated with 
doxycycline. Cells were collected over time as in (B) and absorbance of 
solubilized crystal violet in each experimental plate was normalized to cells at 






EDD stable knockdown sensitizes UM22B cells to cisp latin 
 Similar to the colony formation assay performed in Figure 4.4, UM22B 
stable populations from Figure 4.5A (scrambled shRNA and EDD UTR targeting 
shRNA expressing) were treated with cisplatin for 2 hours and colonies were 
allowed to recover for three days. Cells were treated with different concentrations 
of cisplatin (0, 10, 15, 20, 30, or 40 µM). Results in Figure 4.6A show that at 
certain concentrations of cisplatin, UM22B EDD stable knockdown cells are more 
sensitive to cisplatin than their scrambled control shRNA counterparts. At a 20 
µM dose of cisplatin, EDD knockdown cells are 37% more sensitive to cisplatin 
than the scrambled control cell line. This is consistent with results from O’Brien et 
al. which demonstrated a similar effect in A2780 cisplatin resistant cells treated 
with either scrambled siRNA or EDD siRNA and treated with a 20 µM dose of 
cisplatin (approximately 40% increase in sensitivity) (O'Brien, Davies et al. 2008). 
Similar to results in Figure 4.5B, Figure 4.6B illustrates that the colony size in 
scrambled and EDD shRNA expressing stable cell lines is relatively the same, 
indicating that EDD knockdown is not affecting the rate of proliferation in these 
cells. A visual representation of the colonies counted in Figure 4.6A is displayed 
in Figure 4.6C (UM22B scrambled shRNA expressing cells) and Figure 4.6D 
(UM22B EDD UTR targeting shRNA expressing cells). Although there is a 
qualitative difference in the number of colonies present in cells treated with 15 
µM, 20 µM, and 30 µM doses of cisplatin indicating that EDD stable knockdown 
increases cisplatin sensitivity in UM22B cells treated with these certain doses of 
cisplatin, otherwise the effect is not significant. These results demonstrate a 
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trend towards EDD knockdown fostering cisplatin sensitivity, but more 







Figure 4.6. UM22B stable EDD knockdown cell lines demonstrate increased 
cisplatin sensitivity. (A) UM22B scrambled shRNA and EDD UTR shRNA cell 
lines from Figure 4.5A were tested in a colony formation assay to detect changes 
in cisplatin sensitivity. Cells were plated sparsely and treated with increasing 
concentrations of cisplatin (0, 10, 15, 20, 30, or 40 µM) for 2 hours and then 
colonies were allowed to grow for 3 days. Colonies were counted and normalized 
to the amount of colonies on the untreated plates. (B) Colonies from (A) were 
analyzed for average colony size to determine any differences in the rate of 
proliferation in the two different stable cell lines. Pictures of the colonies analyzed 
in (A) and (B) are depicted in (C) UM22B scrambled control shRNA 









 There are certain parallels between ovarian cancer and oral squamous 
cell carcinoma cell lines in regards to EDD. As in ovarian cancer, EDD 
knockdown in some oral squamous cell carcinoma cell lines promotes apoptosis, 
although unlike ovarian cancer, this does not appear to be through regulation of 
Mcl-1. EDD knockdown, either transiently or stably, also increases cisplatin 
sensitivity in some oral squamous cell carcinoma cell lines. The edd gene is 
overamplified in 50% of oral squamous cell carcinoma of the tongue and in 47% 
of all types of ovarian cancer (Clancy, Henderson et al. 2003). A commonality 
between these two completely different types of cancer that led me to believe 
that EDD may be involved in their cellular signaling process is that in addition to 
the amplification of edd, both are commonly treated with the DNA-damaging 
chemotherapeutic cisplatin and both cancers often display resistance to this 
drug. As I have previously shown in ovarian cancer, EDD mediates cellular 
survival through the transcriptional regulation of the anti-apoptotic protein Mcl-1 
and promotes cisplatin resistance through EDD’s ubiquitin ligase function 
(Bradley, Zheng et al. 2014). Before beginning this project exploring the 
relationship between EDD and oral squamous cell carcinoma, there was no 
connection between this ubiquitin ligase and this cancer other than its gene 
amplification.  
 Presently, the data provided in this chapter demonstrate that the EDD 
protein is highly expressed in oral squamous cell carcinoma cell lines and loss of 
EDD, in addition to promoting apoptosis in some of these cell lines, can also 
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cause cisplatin sensitivity. EDD knockdown induced apoptosis did not appear to 
be dependent on regulation of the anti-apoptotic protein Mcl-1. Mcl-1 protein 
expression levels were not consistently decreased in response to EDD 
knockdown as was seen in ovarian cancer cell lines. This indicates that some of 
these cell lines may not be dependent on Mcl-1 or EDD for cellular survival. As 
expected, oral squamous cell carcinoma cell lines use different cellular signaling 
pathways to regulate survival than ovarian cancer and this can also vary between 
cell lines. Bcl-2 may play a more important role in regulating survival in these cell 
lines since it has been linked to tumor progression in oral squamous cell 
carcinoma (Chen, Kayano et al. 2000).  
 Cell lines (SCC9, SCC25, UM11B) which experienced effective 
knockdown of EDD in response to siRNA transfection were also more sensitive 
to cisplatin. More significantly, one cell line (UM11A), which was consistently not 
susceptible to EDD knockdown induced apoptosis or cisplatin treatment, was 
sensitive to the combination of the two. This indicates that transient knockdown 
of EDD may not be regulating survival in this particular cell line, but it can control 
cisplatin sensitivity. In order to separate EDD’s role in maintaining cellular 
survival and cisplatin resistance, EDD stable knockdown cell lines were created. 
In these cell lines, created with an inducible EDD shRNA, induction of EDD 
knockdown did not cause apoptosis as with siRNA mediated knockdown, further 
complicating our understanding of signaling pathways in these cells and EDD’s 
potential role to promote survival. These stable cell lines may have adopted 
alternative signaling pathways to allow for survival without the presence of EDD. 
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 As seen previously, different cell lines can have vastly different responses 
in regards to EDD’s regulation of cisplatin resistance. In UM74B cells, there was 
no clear evidence of EDD stable knockdown cells experiencing increased 
apoptosis when treated with cisplatin. In this cell line, it appears that loss of EDD 
may reduce proliferation when cells are treated with cisplatin. UM74B EDD stable 
knockdown cells also demonstrated inconsistent results in proliferation assays 
without cisplatin treatment, indicating that these cells may exhibit defects in 
proliferation due to EDD knockdown.  This is explicable because EDD has been 
previously shown in multiple publications to regulate the cell cycle and response 
to DNA damage (Henderson, Russell et al. 2002, Gupta, Chakrobarty et al. 2006, 
Henderson, Munoz et al. 2006, Munoz, Saunders et al. 2007, Ling and Lin 2011, 
Smits 2012). Additional experiments need to be completed in UM74B EDD stable 
knockdown cells to examine their ability to respond to other DNA damaging 
agents and the mechanism behind this response. Alternatively in UM22B cells 
with a stable knockdown of EDD, there was no effect on the proliferation of these 
cells when treated with cisplatin. Results from colony formation assays in UM22B 
cells indicated that EDD loss in these cells increases cisplatin sensitivity at 
certain concentrations of cisplatin (20 µM and 30 µM), which is comparable to 
results shown in O’Brien’s research (O'Brien, Davies et al. 2008). The results 
described above are summarized in Table 4.1.  
 Based on these results, it is difficult to draw a direct connection between 
EDD and cellular survival or cisplatin resistance, but further experimentation with 
other oral squamous cell carcinoma cell lines may lead to more conclusions. The 
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cell lines used in these experiments generated considerably different results, so 
further exploration of other cell lines may prove to be more beneficial than trying 
to focus on a few distinct cell lines. Alternatively, these cell lines (UM74B and 
UM22B) could be used for more mechanistic studies to determine the cellular 
signaling pathways utilized by each cell line to control responses to DNA 
damage, survival, and proliferation. This would allow the delineation of DNA 
damage response pathways and cell cycle control pathways in UM74B cells 
which demonstrate an alternative rate of proliferation. Ubiquitin ligase function of 
EDD could be further explored in UM22B cells, as these cells exhibit increased 
cisplatin sensitivity due to the loss of EDD, but only at certain concentrations of 
cisplatin. This suggests that a balance may be occurring in these cells between 
initial response to DNA damage and a pathway regulated by EDD’s ubiquitination 





Table 4.1.  
 EDD siRNA  EDD shRNA  











Apoptosis  Increased 
Cisplatin 
Sensitivity 
UM11A Yes No Yes Not tested Not tested Not tested 
UM11B Yes Yes Yes Not tested Not tested Not tested 
UM74B Yes Yes Inefficient 
knockdown 
Yes No Reduced 
proliferation 
Scc9 Yes Yes Yes Not tested Not tested Not tested 
Scc25 Yes Yes Yes Not tested Not tested Not tested 
UM22B Not tested Not tested Not tested Yes No Increased: 
14% at 15 µM 
37% at 20 µM 
33% at 30 µM 
 
Table 4.1. Effects of transient and stable EDD knockdown on apoptosis and 
cisplatin sensitivity. Summary of results depicted in Figures 4.1- 4.6 regarding 















 The purpose of this dissertation is to examine the role of the E3 ubiquitin 
ligase EDD in modulating cellular survival and cisplatin resistance in both ovarian 
cancer and oral squamous cell carcinoma. My experimental approach is as 
follows: 1) establish if EDD knockdown with siRNA induces apoptosis; 2) 
examine alterations in pro-apoptotic proteins and anti-apoptotic proteins in 
response to EDD knockdown induced apoptosis; 3) determine the mechanism by 
which EDD alters expression of apoptosis regulatory proteins; 4) determine if 
EDD knockdown transiently or stably promotes cisplatin sensitivity in vitro and in 
vivo; 5) establish if EDD overexpression is sufficient to promote cisplatin 
resistance; 6) resolve if EDD knockdown transiently or stably induces apoptosis 
and increases cisplatin sensitivity in oral squamous cell carcinoma.  
 EDD knockdown induces apoptosis through transcript ional 
regulation of Mcl-1 
 Since EDD is overexpressed in ovarian cancer and oral squamous cell 
carcinoma, siRNA was used to knockdown EDD in order to determine what 
cellular processes required EDD. When EDD is knocked down, cells undergo 
apoptosis, which is accompanied by a consistent loss in the anti-apoptotic protein 
Mcl-1 in ovarian cancer cell lines. EDD knockdown with siRNA in SCC25, 
UM11B, and UM74B oral squamous cell carcinoma cell lines causes apoptosis, 
without a consistent change in Mcl-1. This indicates the variety of cellular 
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signaling pathways employed by these cell lines as compared to other oral 
squamous cell carcinoma cell lines tested and the signaling pathways in ovarian 
cancer cell lines.  
 In ovarian cancer, even when apoptosis is inhibited before EDD 
knockdown can cause cleavage of caspases, Mcl-1 protein expression is still 
decreased. These cells apparently have an equal requirement for EDD and Mcl-1 
for cellular survival as a loss of either results in 23% apoptosis in ES-2 cells and 
41% in A2780-ip2 cells. Overexpression of Mcl-1 is sufficient to protect cells from 
EDD knockdown induced apoptosis, even though EDD knockdown still results in 
a loss of endogenous Mcl-1. Due to the alternative regulation of endogenous 
versus exogenous Mcl-1, this led to the deduction that EDD is regulating Mcl-1 at 
its promoter, since the exogenous Mcl-1 is driven by a CMV promoter instead of 
the endogenous promoter. This assumption was supported by real time PCR in 
which EDD knockdown causes a 1.87 fold decrease in Mcl-1 mRNA. 
Furthermore, both wild-type EDD and an EDD mutant which lacks ubiquitin ligase 
activity were both found to activate transcription from either a direct or indirect 
action on the mcl-1 promoter as found in Mcl-1 promoter driven luciferase 
assays. These results illustrate that EDD enhances cellular survival in ovarian 
cancer cell lines through transcriptional regulation of mcl-1 at its promoter. 
Furthermore, this is independent of EDD’s ubiquitin ligase activity.  
 EDD knockdown sensitizes cells to cisplatin 
 In addition to being overexpressed in ovarian and oral squamous cell 
carcinoma of the tongue, EDD is also associated with a 2-fold increased risk of 
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disease recurrence and death in patients that initially responded to 
chemotherapy treatment (Clancy, Henderson et al. 2003, O'Brien, Davies et al. 
2008). In addition, the amplification of the chromosomal region surrounding EDD 
is associated with cisplatin resistance (Wasenius, Jekunen et al. 1997, 
Callaghan, Russell et al. 1998). To determine the significance of EDD in 
regulating cisplatin resistance in ovarian cancer and oral squamous cell 
carcinoma of the tongue, EDD was knocked down transiently with siRNA or 
stably with shRNA. In the ovarian cancer cell line ES-2, knockdown of EDD with 
siRNA causes apoptosis alone, but when combined with a low dose of cisplatin 
treatment, this considerably enhances apoptosis in this cell line. In another 
ovarian cancer cell A2780-ip2, knockdown of EDD with siRNA caused such a 
substantial amount of apoptosis that it masked any additional effect from cisplatin 
treatment. To separate EDD’s functions regarding EDD knockdown induced 
apoptosis and increased cisplatin sensitivity, EDD stable knockdown cell lines 
were created with EDD shRNA. These cell lines confirmed results that EDD 
knockdown increases cisplatin sensitivity across three ovarian cancer cell lines. 
EDD stable knockdown cell lines did not show a decrease in the anti-apoptotic 
protein Mcl-1 indicating that these two functions of EDD are separate.  
 Transient knockdown of EDD with siRNA increases cisplatin sensitivity in 
some oral squamous cell carcinoma cell lines, such as SCC9, SCC25, UM11B, 
and UM11A. Unexpectedly, UM11A cells, which are typically not sensitive to 
EDD knockdown induced apoptosis, experienced apoptosis when treated with 
both EDD siRNA and cisplatin. This again supports the display of variety across 
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the oral squamous cell carcinoma cell lines as well as confirms a role for EDD in 
regulating cisplatin sensitivity. This diversity also creates variability in the results 
observed in UM74B and UM22B cells with a stable knockdown of EDD using 
shRNA expression. UM74B cells appear to exhibit a slower rate of proliferation 
when EDD is lost in EDD shRNA stable expressing cells as compared to control 
shRNA expressing cells when these cells are treated with cisplatin. Inversely, 
UM22B cells with stable knockdown of EDD do not exhibit any alterations in 
proliferation with or without cisplatin treatment. These UM22B stable EDD 
knockdown cell lines do demonstrate a trend of increased cisplatin sensitivity due 
to EDD stable knockdown at certain cisplatin concentrations (20 µM and 30 µM). 
Thus, while more experiments are needed in the oral squamous cell carcinoma 
cell lines to examine various cell lines, analysis in both ovarian cancer and oral 
squamous cell carcinoma demonstrates that knockdown of EDD, transiently and 
stably, increases cisplatin sensitivity.  
 EDD overexpression is sufficient to promote cispla tin resistance, 
 dependent on its ubiquitin ligase activity 
 In order to determine the significance of EDD overexpression in 
relationship to cisplatin resistance, COS-7 cells were transfected with GFP 
(control), wild-type EDD, or C2768A EDD mutant (ubiquitin ligase defective). 
After treatment with cisplatin, the percentage of those cells undergoing apoptosis 
was measured using a kit that enabled detection by microscopy. Cells that were 
transfected with wild-type EDD had significantly fewer cells undergoing apoptosis 
due to cisplatin treatment, indicating increased cisplatin resistance in these cells. 
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Cells transfected with the ubiquitin ligase defective mutant of EDD (C2768A) did 
not increase cisplatin resistance in these cells when compared to the GFP 
control transfected cells. As this mutant differs at only one amino acid (cysteine 
2768 to alanine), which prevents ubiquitin transfer to a substrate of EDD, this 
implies that the ubiquitin ligase function of EDD is required to mediate cisplatin 
resistance in these cells. While these experiments were performed in a non-
cancerous cell line, this indicates that EDD is sufficient when overexpressed to 
promote cisplatin resistance, which may be translatable to cancerous cells since 
EDD knockdown increases cisplatin sensitivity in these cells lines. Stable cell 
lines overexpressing EDD or better transfection efficiency is necessary before 
similar experiments could be performed in cancerous cell lines.  
 EDD is a potential therapeutic target in ovarian ca ncer 
 E3 ubiquitin ligases have a catalytic domain, but do not possess a defined 
catalytic pocket that would allow small molecule inhibitors to bind. For this 
reason, DOPC liposome nanoparticles which encapsulate siRNA targeting EDD 
were utilized by our collaborators to deliver EDD siRNA in vivo to athymic nude 
mice xenograft models of ovarian cancer. Mice were injected with ovarian cancer 
cell lines (ES-2 or A2780-ip2) intraperitoneally and tumors were allowed to 
develop for one week. Then mice were treated with control or EDD siRNA in 
nanoparticles with or without cisplatin treatment. After four weeks of treatment, 
tumors were harvested to reveal that EDD siRNA (without cisplatin) caused a 
decrease in tumor burden and when EDD siRNA was combined with cisplatin 
treatment this caused a significant reduction in total tumor burden (ES-2 – 
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77.9%; A2780-ip2-75.9% reduction compared to control siRNA only treated). 
This provides further support for the knockdown of EDD promoting apoptosis and 
enhancing cisplatin sensitivity by demonstrating this effect in vivo as a potential 
therapeutic strategy. The DOPC liposome nanoparticles encapsulating EDD 
siRNA to knockdown EDD is a more attractive therapeutic strategy because loss 
of EDD would decrease cellular survival while also increasing cisplatin sensitivity. 
If a small molecule inhibitor was used, it would likely only affect one of these two 
pathways (either survival or cisplatin sensitivity) since these two pathways are 
functionally distinct based on the function of EDD as either a transcriptional co-
activator or an E3 ubiquitin ligase.  
 Conclusion 
 In conclusion, this dissertation demonstrates that EDD regulates cellular 
survival and cisplatin resistance in both ovarian cancer and oral squamous cell 
carcinoma. In ovarian cancer, EDD regulates the transcription of the anti-
apoptotic protein Mcl-1 at both proximal and distal regions of its promoter. This 
occurs most likely by EDD acting as a transcriptional co-activator either directly 
or indirectly. As a result of EDD’s regulation of Mcl-1, knockdown of EDD 
transiently with siRNA promotes apoptosis. Knockdown of EDD, transiently or 
stably, increases cisplatin sensitivity in ovarian cancer. Correspondingly, EDD 
overexpression is sufficient to increase cisplatin resistance which is dependent 
on its ubiquitin ligase function. These results are also confirmed by in vivo mouse 
xenograft studies which exhibit EDD knockdown with DOPC liposome 
nanoparticles encapsulating siRNA can sensitize ovarian tumors to cisplatin.  
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 In oral squamous cell carcinoma cells lines, diversity among the cell lines 
generates different results depending on the cell line used. Transient knockdown 
of EDD causes apoptosis in most oral squamous cell carcinoma cell lines, but 
this effect does not appear to be dependent on regulation of Mcl-1. Stable 
knockdown of EDD causes a reduced rate of proliferation when UM74B cells are 
treated with cisplatin and knockdown of EDD increases cisplatin sensitivity in 





Context in the Field 
 While initial therapies for both ovarian and oral squamous cell carcinomas 
are surgical debulking, chemotherapy often follows especially in highly 
aggressive cases. Resistance to chemotherapy, such as the DNA damaging 
agent cisplatin, is very common. The research in this dissertation concludes that 
the E3 ubiquitin ligase EDD is involved with mediating cisplatin resistance in 
these cancers. This is of significant importance because the edd gene is 
overamplified in both of these types of cancers, including breast, hepatocellular 
carcinoma, and metastatic melanoma (Clancy, Henderson et al. 2003, Fuja, Lin 
et al. 2004). Previously my mentor Scott Eblen also identified EDD as a direct 
substrate of ERK2, implicating EDD as a valuable protein involved in mediating 
cell signaling process (Henderson, Russell et al. 2002, Eblen, Kumar et al. 2003, 
Bethard, Zheng et al. 2011). There are numerous publications describing EDD’s 
roles in DNA damage response, cell cycle control, and transcriptional co-
activator. This dissertation research expands upon this knowledge and integrates 
it to further demonstrate EDD as a regulator of Mcl-1 transcription to promote 
cellular survival and illustrate EDD as an E3 ubiquitin ligase that is sufficient to 
increase cisplatin resistance. While more mechanistic studies are needed to 
delineate the effectors EDD is interacting with or ubiquitinating to elicit these 
effects, this research is critical to establishing EDD as a regulator of cell survival 
and drug resistance in two different cancers in which EDD is overexpressed.  
 EDD was first identified as an ortholog in Drosophila melanogaster which 
identified EDD as a critical regulator of proliferation and differentiation (Mansfield, 
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Hersperger et al. 1994). This role is supported by my findings that EDD regulates 
cellular survival and may control cellular proliferation in certain oral squamous 
cell carcinoma cell lines. Similarly, EDD’s role as a transcriptional co-activator for 
myocardin, the vitamin D receptor, and the progesterone receptor to control 
progestin-induced genes independent of ubiquitin ligase function (Henderson, 
Russell et al. 2002, Hu, Wang et al. 2010) is supported by this research. In 
addition, EDD regulated the transcription of ACVRL1 to modulate angiogenesis, 
and this was also shown to be independent of ubiquitin ligase activity (Chen, 
Yang et al. 2013). My documentation of EDD as a transcriptional regulator at the 
Mcl-1 promoter further confirms EDD’s role as a transcriptional co-activator, 
independent of its ubiquitin ligase activity. Further research is needed to 
determine which transcription factors EDD is controlling, either directly or 
indirectly, to affect transcription.  
 In patients that initially responded to chemotherapy, EDD is associated 
with a 2-fold increased risk of disease recurrence and death (O'Brien, Davies et 
al. 2008). On a genetic level, the amplification of the chromosomal region 
surrounding EDD is also linked to increased cisplatin resistance (Wasenius, 
Jekunen et al. 1997, Callaghan, Russell et al. 1998). Numerous studies have 
been published regarding proteins that may regulate cisplatin resistance, but 
most of this research has not been able to establish if their protein of interest is 
sufficient to induce cisplatin resistance. My research builds on the foundations of 
these studies establishing potential mechanisms of cisplatin resistance to include 
results demonstrating that EDD overexpression is sufficient to promote cisplatin 
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resistance, dependent on its ubiquitin ligase activity (Bradley, Zheng et al. 2014). 
In addition, my research also confirms that knockdown of EDD increases 
cisplatin sensitivity in ovarian cancer. Preliminary results in oral squamous cell 
carcinoma cell lines also support this conclusion to expand this knowledge 
across distinct types of cancers.  
 EDD facilitates the DNA damage response that could be occurring in 
these cells as a result of cisplatin treatment through the ubiquitination and 
designated degradation of Topoisomerase II-binding protein (TopBP1) to prevent 
protection of DNA damaged chromosome ends (Honda, Tojo et al. 2002). 
Similarly, EDD interacts with CHK2, a checkpoint kinase during DNA damage, 
and enables its activating phosphorylation in order to arrest the DNA damaged 
cells in mitosis to allow for repair (Henderson, Munoz et al. 2006). Loss of EDD 
disrupts cell cycle checkpoints leading to premature, unregulated mitosis and 
thus polyploidy (Munoz, Saunders et al. 2007). Recently EDD has also been 
shown to cooperate with TRIP12 to maintain RNF168 expression to aid in the 
prevention of chromatin ubiquitin spreading to undamaged chromosomes 
(Gudjonsson, Altmeyer et al. 2012, Okamoto, Bartocci et al. 2013). While EDD’s 
regulation of these proteins was not analyzed in my experiments, my results 
demonstrating EDD increases cisplatin resistance further confirms that EDD has 
a role in regulating DNA damage response and narrows down EDD’s role as that 
of an E3 ubiquitin ligase. 
 Presently, the only relationship that has been established between EDD 
and oral squamous cell carcinoma is the gene amplification of edd. Despite the 
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various cellular signaling pathways employed by the oral squamous cell 
carcinoma cell lines, my results demonstrate that EDD regulates cellular survival 
in a subset of these cell lines. While more experiments are needed to be able to 
make direct conclusions, stable knockdown of EDD seems to slow cellular 
proliferation due to cisplatin treatment in UM74B cells and knockdown appears to 
cause a trend towards increasing cisplatin sensitivity in UM22B cells. The effects 
seen in the UM74B cells can be explained based on previous research 
describing EDD’s ability to regulate the cell cycle and DNA damage response 
(Mansfield, Hersperger et al. 1994, Henderson, Russell et al. 2002, Gupta, 
Chakrobarty et al. 2006, Henderson, Munoz et al. 2006, Munoz, Saunders et al. 
2007, Ling and Lin 2011, Smits 2012).  
 





 Determine the transcriptional co-factor(s) require d for EDD’s 
regulation of mcl-1 transcription 
 Published results from this dissertation identify EDD as a transcriptional 
co-activator for the transcription of the anti-apoptotic protein Mcl-1, which 
regulates cellular survival in ovarian cancer cell lines (Bradley, Zheng et al. 
2014). This effect was determined to be independent of EDD’s ubiquitin ligase 
activity. Henderson et al. has also established EDD as a transcriptional co-
activator with the progesterone receptor through an interaction in the middle 
section of EDD. Transcriptional regulation of Mcl-1 has been highly studied to 
demonstrate that Mcl-1 transcription is regulated by several different transcription 
factors. In studying the overlap between proteins EDD interacts with and those 
that regulate Mcl-1 transcription, β-catenin, E2F1, and GATA-2 were identified. β-
catenin and hypoxia-inducible factor 1 α cooperate in prostate cancer cells as a 
result of platelet-derived growth factor stimulation to increase mcl-1 transcription 
(Iqbal, Zhang et al. 2012). EDD has been identified to ubiquitinate and therefore 
stabilize β-catenin to promote its activity (Hay-Koren, Caspi et al. 2011). It stands 
to reason that EDD overexpression in cancer could increase ubiquitination of β-
catenin, which results in enhanced mcl-1 transcription. The knockdown of EDD 
increased protein expression of the E2F transcription factor 1, which can 
decrease mcl-1 transcription (Croxton, Ma et al. 2002, Croxton, Ma et al. 2002, 
Munoz, Saunders et al. 2007). Thus, overexpression of EDD in cancer could 
decrease E2F1 expression, allowing mcl-1 transcription. Furthermore, 
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transcription factor software identified several transcription factors, such as 
GATA-2, that regulate mcl-1 transcription (TFSEARCH). As mentioned above, 
EDD acts as a transcriptional co-activator for the progesterone receptor, and this 
receptor also interacts with GATA-2 in breast cancer cells (Henderson, Russell et 
al. 2002, Magklara and Smith 2009). This suggests that EDD could interact as 
part of a complex between the progesterone receptor and GATA-2 at the Mcl-1 
promoter. Co-immunoprecipitations could be used to identify any of these 
transcription factors, or other potential transcription factors, as an interacting 
partner of EDD. Additionally, transfection of one of these transcription factors 
along with EDD transfection in cells with the mcl-1 promoter-driven luciferase 
assay would determine if any of these transcription factors has the potential to 
cooperate with EDD in order to increase mcl-1 transcription. In the case of E2F1, 
transfection of this transcription factor would decrease mcl-1 transcription, unless 
overexpression of EDD has an overwhelming function to decrease E2F1 protein 
expression before it can exert its inhibition of mcl-1 transcription. Further analysis 
is needed to determine which transcription factors EDD interacts with, either 
directly or indirectly as part of a complex, and whether this has an effect on mcl-1 
transcription.     
  
 Identify novel targets of EDD ubiquitin ligase act ivity that are 
involved in mediating acquired cisplatin resistance  
 The function of EDD as an E3 ubiquitin ligase is essential for EDD to 
mediate cisplatin resistance. While a few substrates of EDD’s ubiquitin ligase 
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function have been established, none of these have been established as a direct 
link between EDD and cisplatin resistance. EDD may promote substrate 
degradation, as with PAIP2, or it may promote protein stabilization, as with β-
catenin as a result of substrate ubiquitination (Yoshida, Yoshida et al. 2006, Hay-
Koren, Caspi et al. 2011). In order to determine which substrates are 
ubiquitinated by EDD, an inducible stable EDD overexpressing cell line would be 
used to overexpress either wild-type EDD or the ubiquitin ligase defective mutant 
(Cys2768Ala). In order to create these inducible stable overexpressers, a 
piggybac transposon-based expression system will be used. Based on a 
publication from  James Rini’s lab, the piggyback Rfa plasmid will be used to 
encode the EDD gene, a transposase plasmid used for cutting and inserting the 
plasmids into the cell genome, and  a PB-RB plasmid to encode the reverse 
tetracycline-controlled transactivator (rtTA) which includes the tetracycline 
repressor and the transactivation domain (Li, Michael et al. 2013). This Tet-on 
system will allow for the addition of doxycycline to cells in order to turn on 
expression of EDD. Previously, I made these stable cell lines in HEK 293T cells 
and Cos-1 cells, but very few of the cells express EDD after selection in both 
puromycin (selects for the Rfa-EDD plasmid) and blasticidin (selects for rtTA 
expression). To mitigate this problem, I made Rfa plasmids encoding EDD fused 
to GFP. This will allow for me to select for cells by florescent automated cell 
sorting (FACS) to isolate only those cells which express either GFP wild-type 
EDD or GFP Cys2768Ala EDD. Currently, at the time of the writing of this 
dissertation, HEK293T and HeLa cells transfected with these plasmids have 
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been used to create these inducible stable EDD overexpressing cell lines as 
demonstrated in Figure 5.1.  
 These stable EDD overexpressing cell lines will be used to identify 
ubiquitinated substrates through an unbiased proteomics screen. Cells will be 
cultured in either light (12C6-Lysine, 
12C6-Arginine) or heavy (
13C6-Lysine, 
13C6-
Arginine) SILAC media for 6 passages. For example wild type EDD 
overexpressers would be cultured in light media while the ubiquitin defective 
mutant EDD overexpressers would be cultured in heavy media. About 6 hours 
before collection of the cells, the proteasome inhibitor MG132 will be added to 
allow for the accumulation of ubiquitinated proteins. Trypsin digestion will cut 
proteins at lysine residues. Immunoprecipitation using an anti-digylcyl lysine 
antibody will bind exposed lysine residues on ubiquitin chains on peptides. The 
objective is to identify proteins which are ubiquitinated in the wild type EDD 
overexpressing cells but not in the Cys2768Ala EDD overexpressing cells. 
Multiple replicates would be required for this experiment, also switching the 
SILAC media between wild type and mutant EDD to control for differences in 
SILAC incorporation, in order to monitor reproducibility of the identified 
substrates. The basic experimental outline for this is depicted in Figure 5.2.  
 Once targets of EDD’s ubiquitin ligase activity are established by mass 
spectrometry analysis, these targets would be validated through in vitro 
ubiquitination assays. The targets which may play a role in DNA damage 
response, cellular survival, and cisplatin sensitivity would be analyzed further 
through knockdown and overexpression studies. This would allow for conclusions 
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to be drawn about whether a substrate is involved in mediating cisplatin 
resistance in ovarian cancer cell lines. It is expected that substrates identified will 
play a role in DNA damage repair pathways (such as TOPBP1), apoptotic 
pathways, proliferation pathways (such as downstream effectors of ERK or Akt), 
transcription (such as β-catenin and the progesterone receptor), translation (such 
as PAIP2), and cell cycle control (such as katanin). The results from this would 
elucidate the mechanism by which EDD increases cisplatin resistance in cancer, 
as examined in aim 2 (Chapter 3).  
 
Figure 5.1.  
 
Figure 5.1.  Stable GFP-EDD overexpressing cell lines. HeLa and HEK 293T cell 
lines were transfected with either empty Rfa vector control, GFP-Wild type EDD 
Rfa, or GFP-Cysteine mutant EDD Rfa vector. These cell line populations were 
selected with blasticidin and puromycin. Expression of GFP-EDD was induced 
with different concentrations of doxycycline.   
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Figure 5.2 Mass spectrometry analysis of ubiquitinated proteins from EDD 
overexpressing cell lines. Inducible stable overexpression cell lines, both wild 
type EDD and cysteine mutant of EDD, will be grown in SILAC media, either 
heavy or light, for 6 passages. MG132 will be added 6 hours before collection. 
Cell lysates will be mixed together and ubiquitinated proteins will be 
immunoprecipitated using an antibody to the lysine-glycine-glycine remnant on 
ubiquitinated proteins after trypsin digestion. Proteins will be separated by SDS-






Drug screen for compounds that will enhance cisplat in sensitivity when 
EDD is overexpressed 
 Typically, E3 ubiquitin ligases are not easily targeted by small molecule 
inhibitors due to the lack of a defined catalytic pocket. Rather E3 ubiquitin 
ligases, such as EDD, rely on protein-protein interactions across multiple 
domains on the protein allowing for ubiquitin, an E2 enzyme, and a substrate to 
bind to the ligase, often simultaneously. My dissertation research identifies EDD 
as an important regulator of cisplatin resistance and cellular survival in ovarian 
cancer, and potentially oral squamous cell carcinoma. Figure 3.6 demonstrates 
the value of knocking down EDD with DOPC liposome nanoparticles 
encapsulating EDD siRNA to increase cisplatin sensitivity in ovarian tumors in 
vivo. SiRNAs are much more difficult to use as a therapeutic than small molecule 
inhibitors. In order to create a therapy based on this research, a drug screen 
could be utilized to identify compounds that could either inhibit EDD, which is 
overexpressed in many cancers, or interact with an interacting partner of EDD in 
order to prevent EDD’s ability to increase cisplatin resistance. In theory, it is likely 
that one of these drugs that enhances cisplatin sensitivity when EDD is 
overexpressed would prevent EDD’s ubiquitination of an unknown substrate 
since EDD increases cisplatin sensitivity through its ubiquitin ligase activity.  
 Utilizing inducible GFP-EDD stable overexpressing cell lines, as detailed 
above, a combination of cisplatin at a sublethal dose (EC10) and 10 µM  of a 
compound from the ChemBridge library would be used to test for compounds 
that enhance cisplatin induced apoptosis, as illustrated in Figure 5.3. A 
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sulforhodamine B cytotoxicity assay (SRB assay) would be used as a high-
throughput screen for compounds which increase cisplatin sensitivity in these 
EDD overexpressing cells as this assay analyzes cell density based on cellular 
protein content as an indirect measure of cellular survival. Approximately 15,000 
compounds from the ChemBridge Library would be screened and the top 0.1% of 
these drugs along with their chemotypes would be validated. These top 
compounds would be tested in a variety of assays (MTT assay, propidium iodide 
staining for apoptosis, and colony formation assays)  in EDD overexpressing 
cells, ovarian cancer cell lines, and primary ascites from MUSC patients, along 
with cisplatin treatment to determine which compounds are effective at increasing 
cisplatin resistance. A future aim of this project is to analyze the mechanism 
which these compounds affect in order to gain a better understanding of the 
signaling pathways EDD is affecting to mediate cisplatin resistance. It is possible 
that compounds would be identified that do not modify EDD or its cellular 
functions, but this approach would still identify compounds which could be useful 
in patients that are treated with cisplatin as a first line therapeutic or patients 





Figure 5.3.  Drug Screen for compounds that increase cisplatin sensitivity. Wild 
type EDD stable overexpressing cells (doxycycline inducible) will be treated with 
a suboptimal dose of cisplatin along different compounds from the ChemBridge 
library. Controls used will 
not treated with cisplatin. A SRB assay will be used to measure cytotoxicity. 










 Analyze alternative responses to stable EDD knockd own in oral 
squamous cell carcinoma cell lines  
 Based on results from aim 3 (Chapter 4), it is apparent that oral squamous 
cell carcinoma cell lines vary in their responses when EDD is knocked down with 
shRNA. In UM22B cells, as expected based on results seen in ovarian cancer 
cell lines, the stable knockdown of EDD sensitizes cells to cisplatin. It should be 
noted that this response only occurred at significant levels at moderate doses of 
cisplatin treatment (20 µM and 30 µM) as shown in Figure 4.6. Since EDD 
mediates cisplatin resistance based on its E3 ubiquitin ligase activity, there may 
be something that EDD ubiquitinates which is responsible for maintaining a fine 
balance in detecting and/or repairing DNA damage. This unknown ubiquitinated 
substrate may be affected when there is a moderate level of DNA damage, but 
DNA damage repair is not effective. As proposed above, it would be valuable to 
create a better assessment of the pathways and substrates that EDD affects 
through the identification of its ubiquitin ligase targets. 
 On the other hand, UM74B cells do not appear to be sensitive to EDD 
knockdown-induced cisplatin sensitivity, although these cells do exhibit slower 
rates of proliferation as a result. Based on these results, an analysis of the DNA 
damage response pathways and cell cycle control pathways as a result of EDD 
stable knockdown with or without cisplatin treatment would be a useful method to 
determine the role(s) EDD is playing in this certain oral squamous cell carcinoma 
cell line. EDD stable knockdown cell lines could be treated with or without 
cisplatin and lysates from these cells could be evaluated by immunoblot for 
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altered expression of proteins involved in mediating DNA damage response and 
cell cycle control. In addition, these stable knockdown cells could be treated with 
other DNA damaging agents such as carboplatin, gemcitabine, etoposide, and 
doxorubicin to determine if these chemotherapeutics also decrease the rate of 
proliferation in these cells when EDD is lost.  
 It is crucial based on these unexpected results in different oral squamous 
cell carcinoma cell lines that the number of cell lines used in aim 3 be expanded. 
This would allow for statistically significant conclusions to be drawn about EDD’s 
role in regulating cellular survival and cisplatin resistance in oral squamous cell 
carcinoma. Once a role for EDD can be established as regulator of cisplatin 
resistance in oral squamous cell carcinoma, stable EDD knockdown cell lines 
can be made and tested in nude mouse xenograft models to confirm these 
results in vivo (Figure 5.4). It is expected that in vivo results would be similar to 
those seen in our ovarian cancer xenograft model in Figure 3.6, which 







Figure 5.4. In vivo model to test increased cisplatin sensitivity due to EDD stable 
knockdown. Nude mice will be injected orthotopically with UM-SCC oral 
squamous cell carcinoma cell lines expressing either EDD shRNA or scrambled 
control shRNA. Once tumors are established, doxycycline will be added to the 
normal mouse chow to induce expression of the shRNA in each tumor. Mice will 
then be treated with either saline control or cisplatin and tumor progression will 
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Establish the role of EDD phosphorylation 
 While the focus of this dissertation is the mechanisms by which EDD 
affects cellular survival and cisplatin resistance, it is critical to gain a better 
understanding of what regulates EDD. One such method of regulation of EDD is 
phosphorylation by ERK2 (Eblen, Kumar et al. 2003). Our lab has also published 
mass spectrometry results identifying 24 sites of phosphorylation (Bethard, 
Zheng et al. 2011). It is currently unknown which kinases, other than ERK2, 
contribute to these sites of phosphorylation. Moreover, it is unknown how 
phosphorylation of EDD regulates its protein stability, localization, and cellular 
functions such as ubiquitin ligase activity and protein-protein interactions. To gain 
a better understanding of these effects, the known sites of phosphorylation of 
EDD could be mutated to alanine to mimic a lack of phosphorylation at any single 
site or a combination of phosphorylation sites. Based on the sites of 
phosphorylation, consensus sites of kinases could be analyzed to determine 
which kinases may be involved in mediating phosphorylation. An in vitro kinase 
assay could then be used to test these kinases to determine if they can 
phosphorylate EDD on these sites, but not when these sites are mutated to 
alanine. Once potential kinases are established that phosphorylated EDD, kinase 
inhibitors could be used to validate phosphorylation by these kinases. These 
inhibitors could also establish how phosphorylation of EDD is required to 
establish protein-protein interactions. These interactions allow for EDD’s activity 
as an ubiquitin ligase and as a transcriptional co-factor, such as for the 
transcriptional regulation of mcl-1. It is also possible that a kinase inhibitor could 
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be used in conjunction with cisplatin treatment if phosphorylation of EDD by this 
kinase is required for ubiquitin ligase activity, thus the kinase inhibitor would 
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